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 Human pharmaceutical waste threatens many natural processes of non-target 
aquatic organisms, through the introduction of such contaminants into the environment. 
Pharmaceuticals are a large and diverse groups of medicinal compounds that are used for 
the diagnosis, cure, mitigation, treatment, and/or prevention of diseases in humans and 
animals. In recent years, the occurrence and fate of pharmaceuticals in the aquatic 
environment have become an emerging issue in aquatic toxicology, with one of the most 
prevalent contaminants being the type-2 diabetic drug, metformin, and its metabolite 
guanylurea. Metformin and guanylurea have been measured in surface waters in the ng- 
µg·L-1 range. This study aimed to investigate the toxicological effects of metformin and 
guanylurea on Japanese medaka (Oryzias medaka).  
 A first experimental step was to determine the potential for uptake, 
bioaccumulation, and depuration of metformin in early-life stage (ELS) medaka using 14C-
metformin. Results from this study showed that both embryo and larval medaka can take 
up, bioaccumulate, and successfully depurate metformin from the aquatic environment. 
Furthermore, egg chorion hardening (~6 hpf) prevented the uptake of metformin from by 
developing embryos.  
 Additionally, we show that waterborne exposure to metformin and guanylurea 
significantly impacted the growth metrics in ELS fish, showing that guanylurea caused 
growth retardation at exposure concentrations an order of magnitude lower that those 
required by the parent compound to exert similar effects. We sought to explain these 
growth effects by investigating potential alterations in the metabolome and gene expression 
of these exposed fish. Several metabolite abundances were altered by the exposure of 
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medaka to 3.2 µg·L-1 metformin and 1.0 ng·L-1 guanylurea, which included metabolites 
associated with cellular energetics, fatty acid synthesis and metabolism, and polyamine 
synthesis. Metabolomic results were applied to select genes of interest for RT-qPCR 
analyses, and the expressions of critical genes involved in lipid metabolism were shown to 
be significantly affected.  
 Furthermore, a full 165 day life-cycle study assessing the effects of metformin and 
guanylurea alone, and in combination, was performed to determine potential population-
level impacts of the compounds on Japanese medaka. While exposure to metformin and 
guanylurea alone, and in combination, did not significantly stunt the growth of medaka, 
exposure to the compounds did alter the production of important sex steroid hormones in 
both male and female medaka. However experimental treatments did not affect the 
production of the egg yolk precursor protein, vitellogenin. Interestingly, no significant 
effect on reproductive output was seen. Collectively, these results underscore the need for 
additional studies examining the effects of metformin and guanylurea on aquatic 
ecosystems. To our knowledge, this research is the first to investigate the effects of 
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 Pharmaceuticals are a large and diverse group of medicinal compounds, used for 
the diagnosis, cure, mitigation, treatment, and/or prevention of diseases in both humans 
and animals (Corcoran et al., 2010). The World Health Organization (WHO) estimated the 
global pharmaceuticals market to be worth $300 billion (USD) yearly, a figure expected to 
rise to US$400 billion within three years. There are substantial regional differences in the 
use of pharmaceuticals internationally, influenced by economic status, health requirements, 
capacity for local manufacture and legal restrictions (Carius and Grüttner, 2014). 
Developed countries dominate global pharmaceutical sales, with North America 
accounting for 45%, Europe 13%, Japan 10%, and Australia 1% of recorded sales (IMS 
Health, 2016). 
 Most of the common pharmaceuticals sold in North America are in drug classes 
used to treat maladies considered to be associated with westernized society, such as 
maintaining cholesterol balance, treating stress, asthma, pain relief, chest pain, bacterial 
infections, and many more. The pharmaceuticals used to treat these maladies include 
specific lipid regulators, beta blockers, corticosteroids, analgesics, antianginal drugs, and 
antibiotics (Jones et al., 2002). In addition to human use, pharmaceuticals are commonly 
used in veterinary practices across North America with antibiotics and antifungals being 
the most common (Corcoran et al., 2010).  
 There is a positive correlation between frequently used classes of pharmaceuticals 
and their detection in the aquatic environment for a variety of reasons, and an inevitable 
consequence of the increase in sales of pharmaceuticals is an increase in consumption, 
leading to an even higher level of discharge into the environment (Corcoran et al., 2010). 
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Pharmaceuticals commonly enter the aquatic environment through human consumption, 
elimination, and disposal, and these pharmaceutical residues are found in the environment 
globally. Based on a review of over 1,000 international publications, pharmaceutical 
residues have been detected in wastewater treatment plant (WWTP) effluent and surface 
waters in 71 countries worldwide ranging from the ng · L-1 to µg · L-1 range in surface 
waters and µg · L-1 range in WWTP effluent (Carius and Grüttner, 2014). Pharmaceuticals 
have also been detected in groundwater, soil and even in drinking water at very low ng · 
L-1 concentrations.  
 The most significant and concerning characteristic of pharmaceuticals in the 
aquatic environment is that these compounds are designed to alter and affect physiological 
functions in target organisms, however, they might adversely affect non-target organisms 
(Carius and Grüttner, 2014). The field of aquatic toxicology investigates the effects of 
anthropogenic and natural compounds on aquatic organisms from the individual through 
to entire communities and ecosystems, aiming to address potential critical issues. Fish 
share many biochemical pathways and physiological similarities with mammals, thus they 
are likely to be susceptible to effects caused by water-borne pharmaceuticals (Corcoran et 
al., 2010).  
 This study investigated the ecotoxicological effects of metformin and its bacterial 
metabolite, guanylurea on Japanese medaka (Oryzias latipes) through a multidisciplinary 
approach combining analytical, molecular, and whole organism laboratory methods to 
analyze uptake, growth, reproductive, genetic, and metabolomic endpoints. This work 
illustrates the necessity for researchers to examine the potential effects of anthropogenic 
compounds like pharmaceuticals on aquatic organisms.  
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1.2 Pharmaceuticals in the environment 
 The fate and occurrence of pharmaceuticals in the aquatic environment has been 
recognized as an emerging issue in environmental science, specifically aquatic toxicology 
(Boxall et al., 2012). A global review of pharmaceuticals in the environment found that of 
the 713 pharmaceuticals tested for, 631 were found above their detection limits in surface 
waters, ground water and even at minute amounts in drinking water (Carius and Grüttner, 
2014). The WHO estimated the pharmaceutical market will increase by 25% over the next 
three years (WHO, 2016), which is concerning, as an inevitable consequence of the 
increase in sales of pharmaceuticals equates to an increase in consumption and consequent 
increases in discharges into the environment.  
 The majority of human pharmaceuticals are taken orally, with gut absorption 
ranging from 0-80% (Holford, 2001). As such, some of these compounds pass directly 
through the patient and are excreted completely unchanged, while other compounds will 
be absorbed by the body, undergo metabolism, and the resultant metabolites excreted via 
the urine and feces. The metabolism of drugs in the human body generally involves 
transformation into more polar and soluble forms to help facilitate drug elimination. The 
process occurs in two phases: phase I, involving oxidation, reduction, or hydrolysis, and 
phase II, involving conjugation of the parent compound to increase solubility (Ardrey, 
2003; Jones et al., 2002; Khetan and Collins, 2007; Testa and Jenner, 1978). Typically, the 
bioavailability of a drug is modulated by cytochrome p450, a superfamily of enzymes used 
to metabolize compounds in the body by converting lipophilic organic molecules to more 
water soluble and reactive compounds by introducing functional groups such as –OH, -SH, 
-NH2, or –COOH during phase I transformations (Celiz et al., 2009; Danielson, 2002). 
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During phase II transformations, these hydrophilic metabolic products then conjugate with  
in vivo molecules to form O- and N-glucuronides, sulfates, acetate esters, carboximides, 
and glutathionyl adducts (Celiz et al., 2009). Since these molecules are now more 
hydrophilic, they can be readily excreted via the kidneys in the urine.  
Once excreted, such pharmaceuticals and their metabolites generally make their 
way into municipal WWTP. The pharmaceuticals and metabolites entering WWTPs may 
or may not undergo biodegradation or biofiltration via activated sludge, followed by 
chlorine, ozonation, oxidation, or activated carbon in order to remove these compounds 
from the water (WHO, 2016). In general, WWTPs were designed to aid in the removal of 
biodegradable carbon, nitrogen, and phosphorus compounds that usually arrive in the plant 
in the high mg/L concentration (Verlicchi et al., 2012).  
The removal of pharmaceuticals through WWTPs has been shown to depend on the 
compound’s chemical characteristics, the treatment processes used, and the concentration 
found in the influent, however other variables may also influence the removal efficiencies 
(Blair et al., 2013; Le-Minh et al., 2010; Oulton et al., 2010; USEPA, 2012; Verlicchi et 
al., 2012). WWTPs have three main mechanisms of removing or degrading pharmaceutical 
compounds: sorption to sludge, biological degradation, and volatilization (Blair et al., 
2013; Khan and Ongerth, 2002). These processes have demonstrated removal rates up to 
90%, however, even with a 90% removal rate, significant amounts of these compounds 
enter the environment daily (WHO, 2016).   
 Aside from human consumption and veterinary use, it should be noted that a small 
portion of prescribed drugs are not ingested or administered, and are disposed of directly 
into landfills or flushed down the toilet to be deposited into wastewaters. It is estimated 
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that in the US alone, $1 billion (USD) of prescription drugs are discarded each year from 
hospitals, care facilities, pharmacies, and in household waste (Strom, 2005). Other sources 
also exist, including emissions and waste from manufacturing sites (Arsson, 2009), 
however the principal route of entry into the environment is a direct result of human 
consumption (Overturf et al., 2015). Pharmaceutical routes of entry are depicted in Figure 


















Figure 1.1: Major routes of entry of pharmaceuticals and personal care products (PPCPs) 









1.3 Pharmaceutical metabolites 
 The majority of studies investigating the amount of pharmaceuticals in the aquatic 
environment have focused on the parent compound with little to no attention, let alone 
quantification, of the transformation products formed during (a) water treatment, (b) human 
metabolic/excretion, and (c) decomposition of the compound. It is easy to recognize that 
pharmaceuticals and their metabolites discharged into the environment are ecologically 
significant, however it is a challenge to assess individual and collective toxicities of parent 
compounds and their metabolites because many metabolites have not yet been identified 
(Celiz et al., 2009). A 2009 review reported that approximately 160 pharmaceutical 
products (both human and veterinary use) and only 30 by-products (biotic and abiotic) have 
been included in environmental occurrence, fate, and ecotoxicological investigations 
(Mompelat et al., 2009).  
 Compound degradation does not always equate to detoxification, as many 
pharmaceutical metabolites bind to proteins and other cellular constituents often causing 
increased cellular function disruption than their parent compound.. For example, the 
glucuronidation of gemfibrozil, a common lipid lowering drug, results in a metabolite that 
is a more potent inhibitor of CYP2C8 (a major drug metabolizing cytochrome P450 
enzyme) than the unconjugated parent drug, which can lead to accumulation and thus toxic 
effects by the inhibition of the metabolism activity of cytochrome P450 enzymes (Celiz et 
al., 2009; Ogilvie et al., 2006). In addition to the potential increase in toxicity of 
metabolites from their parent compounds, the indirect contribution of conjugated 
metabolites should also be considered. Conjugated drug metabolites have the potential to 
undergo deconjugation and transform back to the original form of the parent drug, as 
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commonly seen with both natural and synthetic estrogens (Celiz et al., 2009; Ternes et al., 
1999). The glucuronide forms of estrone and 17β-estradiol are transformed back into their 
active parent estrogens in the environment by Escherichia coli bacteria which possess 
enzymes that facilitate deconjugation of glucuronic acid, such as β-glucuronidase (Celiz et 
al., 2009).  
1.4 Effects of pharmaceuticals on aquatic organisms 
 Pharmaceuticals are biologically active compounds that specifically aim to affect 
control mechanisms in living organisms, for example by influencing hormonal balance, 
alleviating signal transmission between cells, or regulating metabolism in target organisms 
(Carius and Grüttner, 2014). In this sense, target organisms are those receiving the 
pharmaceutical to achieve a desired result. When pharmaceuticals are released into the 
environment, this biological activity may adversely affect non-target organisms such as 
wildlife and impair ecosystem health. Some of these adverse effects have been reported in 
both field and laboratory studies, however many of the effects are still unknown. 
Both the natural estrogen, 17β-estradiol (E2), and the synthetic estrogen, 17β-
ethinylestradiol (EE2), the latter used in common birth control pills, are examples of well-
researched compounds known to have serious adverse effects in fish. In humans, a 
combination of EE2 and progestin are used in the combined oral contraceptive, working to 
prevent ovulation (the release of an egg from an ovary), while also causing changes in the 
cervical mucus and uterine lining, making it harder for sperm to reach the uterus and harder 
for a fertilized egg to attach to the uterus (MedlinePlus Drug Information, 2015: Estrogen 
and Progestin). EE2 has been found in the aquatic environment at low parts per trillion (<5 
ng · L-1) (Kolpin et al., 2002). Male zebrafish (Danio rerio) exposed in the laboratory to 
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0.5-5 ng · L-1 EE2 were shown to produce vitellogenin (VTG) mRNA and protein, early 
stage eggs, as well as decreased spermatozoa in their testes, ultimately leading to increased 
infertility and decreased reproduction (Nash et al., 2004). VTG is normally synthesized by 
female fish and is associated with oocyte maturation as the egg yolk precursor protein; 
therefore increased expression of the protein in males is indicative of endocrine disruption.  
 In addition to laboratory studies showing decreased reproductive success in fish 
exposed to EE2, a 7 year whole lake study, using fathead minnows (Pimephales promelas) 
at the Experimental Lakes Area (ELA) in northwestern Ontario, showed that chronic 
exposure to low concentrations (~ 5 ng · L-1) of the synthetic estrogen led to: feminization 
of males, with the production of VTG mRNA and protein, impacts on gonadal development 
(including  intersex in males), altered oogenesis in females, and ultimately, a near 
extirpation of the species from the lake (Kidd et al., 2007). The concentrations used in both 
of the above studies were comparable to concentrations observed in treated wastewater 
effluent and in surface waters, shown to be > 5 ng · L-1 in many United States streams 
(Kolpin et al., 2002). Both field and lab studies demonstrate that concentrations of EE2 
observed in freshwaters can cause adverse impacts on both individual and population levels 
of biological organization.  
 Aside from synthetic estrogens, hundreds of other pharmaceuticals enter the aquatic 
environment daily. For example, nonsteroidal anti-inflammatory drugs (NSAIDs), such as 
ibuprofen, are found in surface waters in concentrations up to 2.7 µg · L-1. These 
compounds have a therapeutic role to reduce inflammation and pain by inhibiting 
cyclooxygenases (COXs) (Corcoran et al., 2010). COX enzymes are well conserved across 
vertebrate species. One such species, the Japanese medaka (Oryzias latipes), was found to 
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have an altered pattern of spawning and reproduction after being exposed ibuprofen (1-100 
µg · L-1) (Flippin et al., 2007). In the same species, the common anti-depressant fluoxetine 
(surface water concentrations up to 0.030 µg · L-1), commonly known as Prozac, caused 
an increase in estradiol levels at the concentrations 0.1 and 0.5 µg · L-1 (Brooks et al., 
2003). Similarly, egg production and hatching success were both reduced in Japanese 
medaka exposed to 5 µg · L-1 of the beta-blocker, propranolol, commonly used to treat 
cardiac conditions, and found in surface waters at concentrations up to 0.59 µg · L-1 
(Huggett et al., 2002).  
The early life stages of fish are developmentally vulnerable, as shown by 
researchers. The survival of fathead minnow larvae exposed to levonorgestrel from embryo 
through 28 days post hatch was negatively impacted, while growth was also significantly 
reduced compared to controls (Overturf and Huggett, 2015; Overturf et al., 2014). As well, 
levonorgestrel down-regulates natural progestins, a critically responsible component of 
gamete maturation (Overturf et al., 2014). Natural progestin also acts as a pheromone to 
indicate reproductive status, so any perturbations in progestin function can ultimately affect 
successful reproduction of fish (Miura et al., 2006; Overturf et al., 2014; Sorensen et al., 
1987). The early life stages of Japanese medaka are also negatively affected by 
pharmaceuticals such as the widely used dissociative anesthetic, ketamine and the common 
psychedelic, methamphetamine (Liao et al., 2015). Embryonic exposure to 
environmentally relevant levels of ketamine and methamphetamine suppressed the heart 
rate, delayed hatching time and increased the incidence of developmental abnormalities of 
Japanese medaka (Liao et al., 2015). Such results involve only the few compounds tested 
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among the hundreds that enter the environment daily. Thus, additional research on such 
emerging aquatic contaminants is of critical importance for the health of our environment.  
1.5 Metformin and guanylurea 
The anti-diabetic drug metformin is now thought to be the highest drug by weight 
released into the aquatic environment with up to 6 tons per year released from individual 
urban area WWTPs (Crago et al., 2016). In 2013, 72.8 million prescriptions were granted, 
making metformin the 7th most prescribed drug in the United States (IMS Health, 2016). 
Recent studies have found metformin in WWTP effluent at concentrations ranging from 1 
µg · L-1 to 47 µg · L-1, and in surface waters at concentrations ranging from 0.06 µg · L-1 
to 3 µg · L-1 (Niemuth et al., 2015; Oosterhuis et al., 2013; Scheurer et al., 2012). 
 The primary synthesis of metformin in 1922 can be attributed to the work of Werner 
and Bell from Trinity College in Dublin, Ireland (Marić, 2010). In humans, metformin is 
the first line pharmaceutical prescribed to treat patients with type-2 diabetes, and is also 
indicated as a treatment for various cancers as well as for polycystic ovary syndrome 
(PCOS), an endocrine disorder affecting 5-15% of reproductive-age women (Tang et al., 
2012). Despite being one of the most prescribed pharmaceuticals on the market, the exact 
mechanism of metformin action has not been fully elucidated.  
 Metformin does not readily cross cell membranes due to its low lipophilicity; 
therefore, the organic cation transporter 1 (OCT1) has been shown to facilitate cellular 
uptake of metformin (Shu et al., 2007). Deletion of the OCT1 gene in mice dramatically 
reduced metformin uptake in hepatocytes; in addition, human patients carrying 
polymorphisms of the gene (SLC22A1) display an impaired effect of metformin in lowering 
blood glucose levels (Shu et al., 2007). In humans, the SLC22A1 gene is associated with 
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the transport of organic cations across the plasma membrane in both directions, and has 
important functions in pathways related to metabolism and the transport of glucose and 
other sugars (Becker et al., 2009). In diabetes patients, metformin is used to regulate 
glucose levels by the activation of adenosine monophosphate kinase (AMPK), involved in 
regulating metabolism in cells (Crago et al., 2016; Hawley et al., 2010). The activation of 
AMPK then inhibits the target rapamycin (mTOR) signaling pathway that regulates energy 
utilization, thus down-regulating gluconeogenesis in the liver (Crago et al., 2016; 
Goodyear et al., 2001; Kahn et al., 2005; Viollet et al., 2012). In this way, AMPK and 
mTOR play an important role in the metabolism of glucose and fats, whole body energy 
balance and insulin signaling (Crago et al., 2016; Goodyear et al., 2001; Kahn et al., 2005).  
The metformin induced activation of AMPK, resulting in a decrease in mTOR 
mRNA and protein expression, is associated with a decrease in lipid and sterol biosynthesis 
(Goodyear et al., 2001), stimulation of fatty acid oxidation with the inhibition of 
cholesterol and triglyceride synthesis (Li Gonga et al., 2013), increased insulin sensitivity 
(Galardo et al., 2009b), decreased intestinal glucose absorption and inhibition of 
gluconeogenesis, leading to less glucose available for storage in adipose tissue (Igel et al., 
2016; Seifarth et al., 2013), decreased insulin growth factor (Berker et al., 2004; Crago et 
al., 2016), decreased ghrelin secretion (Gagnon et al., 2013) and increased GLP-1 
(glucagon-like peptide-1) levels, leading to an anorectic effect (Mannucci et al., 2001). 
Ghrelin is an orexigenic hormone, produced primarily in the endocrine cells of the stomach, 
which acts to increase appetite and promote energy storage (Gagnon et al., 2013; Horvath 
et al., 2016). GLP-1 is an incretin hormone, secreted from endocrine L cells of the intestine 
in response to nutrients in the gut lumen. GLP-1 conveys an insulinotropic effect via GLP-
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1 receptors on beta cells of the pancreas, inhibiting the secretion of glucagon from the alpha 
cells of the pancreas, which together have a sustained effect on glycemic control (Fink-
Jensen and Vilsbøll, 2016). The increased sensitivity hypothesized to be associated with 
metformin treatment lessens the postprandial hypoglycemia that occurs in insulin resistant 
states, decreasing hypoglycemia induced hunger and carbohydrate craving (Igel et al., 
2016). These effects ultimately drive the weight loss observed in diabetes patients treated 
with metformin (Crago et al., 2016; Goodyear et al., 2001; Kahn et al., 2005). 
 Aside from energy balance, AMPK and mTOR can affect a variety of other 
important pathways like those associated with sexual development, puberty, and thus 
reproduction. By activating AMPK and inhibiting mTOR, metformin is associated with a 
decrease in gonadotropin-releasing hormone (GnRH) secretion, thus decreased follicle 
stimulating hormone subunit beta (FSHβ) (Tosca et al., 2011) and luteinizing hormone 
(LH) and decreased plasma 17β-estradiol levels in rat pituitary cells (Roa and Tena-
Sempere, 2010). Decreases in these hormones have been shown to cause delayed puberty 
in rats (Roa and Tena-Sempere, 2010). In humans, metformin reduces hyperandrogenism 
through its effects on both the ovary and adrenal gland, suppressing their androgen 
production, reducing pituitary LH and increases the production of sex hormone binding 
globulin by the liver (Earle, 2000; Lashen, 2010). In male rats, the decrease in FSHβ 
through the regulation of AMPK and mTOR has been shown to down regulate the 
proliferation of Sertoli cells and the production of sperm (Galardo et al., 2009a). 
 In principle, metformin works in the treatment of polycystic ovary syndrome 
(PCOS) by lowering the circulating insulin levels (Lashen, 2010). Some of the common 
effects reported in relation to metformin in PCOS patients are restoring ovulation, reducing 
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the risk of miscarriage (Lashen, 2010), reducing circulating androgen levels (Earle, 2000), 
and reducing the risk of gestational diabetes mellitus (GDM) (Glueck et al., 2004), 
suggesting that metformin in PCOS pregnancies has a positive effect. Intuitively, the 
multiple impacts on parts of the reproduction pathway listed above could potentially have 
detrimental effects on the reproductive process of non-target organisms, such as fish. 
 Metformin has an average individual daily dose of 2 grams per day (WHO, 2016) 
which is orally administered. Metformin is not metabolized in the human body, thus it is 
excreted unchanged through the urine (about 70%) and the feces (Li Gonga et al., 2012; 
Pentikäinen et al., 1979). Once excreted, such pharmaceuticals and their metabolites 
generally make their way to municipal WWTPs, changed into their metabolite(s), or passed 
through via effluent. To date, guanylurea is the only known recalcitrant, aerobic, bacterial 
degradation product of metformin (Trautwein et al., 2014). Both metformin and guanylurea 
are very polar compounds (Table 1.1) and should be extremely mobile in the aquatic 









Table 1.1: Chemical structure, molecular formula and weight, and pKa of metformin and 
guanylurea.  






Molecular formula C4H11N5 C2H6N4O 
Molecular weight (g/mol) 129.2 102.1 
pKa 2.8a and 12.3 8.0 and 13.5 
logKow -2.64 --- 













 Sampling of five German WWTPs showed a removal rate of metformin of 90% or 
greater (Scheurer et al., 2012). However, due to the extremely high usage of metformin 
and thus high influent concentrations, the effluent levels seen in this study are still between 
the 1.2 µg · L-1 and 10 µg · L-1 range, which are comparable with concentrations of other 
pharmaceuticals that are known to be poorly removed (Scheurer et al., 2012). The removal 
of metformin in WWTPs was directly related to the formation of guanylurea (Trautwein et 
al., 2014). Mean values for metformin and guanylurea found in major rivers in Germany 
are 0.22-1.2 µg · L-1 and 0.1-28 µg · L-1 (Scheurer et al., 2012). Fortunately in this study, 
metformin and guanylurea are shown to be completely removed from raw water treated for 
drinking, explained by aerobic biological degradation, however the products are unknown 
(Scheurer et al., 2012). 
1.5.1 Effects of metformin and guanylurea on fish 
 Metformin’s medicinal use in mammals has been well researched, however the 
effects it has on non-target aquatic organisms, specifically aquatic organisms are still 
unclear. However, some research shows that metformin is known to act in a similar manner 
in fish as it does in mammals. For instance, studies in zebrafish (Danio rerio) show that 
metformin increases insulin induced metabolic rate (Renquist et al., 2013), while the drug 
induced AMPK expression and stimulated glucose uptake in trout muscle (Magnoni et al., 
2012) and liver (Polakof et al., 2011). 
A study conducted by Niemuth et al. (2015), exposed adult fathead minnows 
(Pimephales promelas) (FHM) to µg · L-1 of metformin for 28 days and found that the 
compound significantly increased the egg yolk precursor vitellogenin (VTG) mRNA 
expression, showing that the compound has potential endocrine disruption properties. 
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Another experiment found that male FHM exposed to 40 µg · L-1 metformin from fry (30 
days post hatch) until adulthood (about 1 year) had significantly reduced weight and 
condition factor in metformin exposed fish compared to control fish (Niemuth and Klaper, 
2016). Size can pose a population reproduction problem, as mating pairs of FHM with 
larger males have been shown to be more reproductively successful (Pollock et al., 2008). 
Significant differences were found for cumulative clutches laid per mating pair over time, 
with metformin-treated FHM pairs laying fewer eggs when compared to control pairs 
(Niemuth and Klaper, 2016). Mean clutch size per pair also showed significant differences 
between control and metformin-treated fish, with significantly smaller clutches produced 
for treated fish (Niemuth and Klaper, 2016). In addition, metformin-exposed male FHMs 
also had a significant incidence of intersexuality shown by the occurrence/formation of 
oocytes in males exposed to the compound (Niemuth and Klaper, 2016).  
A recent study shows significant upregulation in gonadal gene targets in male FHM 
exposed to 40 µg · L-1 when compared to control males, specifically genes involved in 
steroid synthesis and metabolism such as: an increase in the androgen receptor, 3β-
hydroxysteroid dehydrogenase (HSD), 17β-HSD, a cytochrome p450 oxidase (CYP19A1), 
and the sulfanotransferase (SULT2A1) (Niemuth and Klaper, 2018). Interestingly, the 
authors observed significant correlations between the expression of 3β-HSD, 17β-HSD, 
and CYP19A1 and the degree of intersex in male FHM gonads represented by the frequent 
perinucleolar follicles and oocyte clumping throughout the testes (Niemuth and Klaper, 
2018).  
To the best of our knowledge, there is no information in the literature regarding the 
effects of guanylurea on aquatic organisms. These findings from a very limited number of 
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studies involving metformin and fish illustrate that the need for more research on the effects 
of metformin, and guanylurea, on aquatic organisms.  
1.6 Japanese medaka research organism 
 Japanese medaka (Oryzias latipes) or rice fish, are small, egg-laying, freshwater 
fish inhabiting water from India throughout Southeast Asia and Japan, and are a common 
teleost in laboratory research settings because of their fully sequenced genome (Iwamatsu, 
2004). At sexual maturity, medaka are about 2.5 to 3 cm in length which is reached within 
3-4 months post hatch (Shima and Shimada, 1994). Medaka are widely used research 
organisms in experimental biology due to many favorable laboratory features: small size, 
easy to maintain, wide availability, multiple strains, daily spawning of reproductive adults, 
noticeable reproductive behavior, visible sexual dimorphism, large and clear embryos, and 
idea development time of embryos (8-10 days), a fully sequenced genome, and the ability 
to effectively observe sexual dimorphisms 3 days post fertilization specifically with the 
female leucophore-free (FLFII) strain of Japanese medaka (Balch et al., 2004; Parenti, 
2008). There are many different strains of medaka, each with valuable characteristics. 
Japanese medaka are very useful for embryo development research. Iwamatsu (2004) 
published a detailed paper outlining the staging of normal development of medaka 
embryos. Because medaka embryos are clear, it allows their development to be monitored 
fully monitored through hatch. 
 The research in this dissertation was performed using the female leucophore-free 
(FLFII) strain, obtained from the National Institute for Basic Biology (Okazaki, Japan), 
and originally introduced by Wakamatsu et al., (2003). The FLFII strain has three 
observable sexual dimorphisms: two markers for body color and a male/female specific 
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DNA marker, SL1. Females of this strain do not produce the leucophore pigment cells, 
while males are wild type for leucophores. This allows for gender identification, and thus 
separation, as early as 3 days post fertilization under a fluorescence microscope. Juvenile 
medaka can be identified by the presence of orange-red xanthophores which are present in 
the males and absent in the females, which become increasingly apparent as the fish age. 
Lastly, definitive gender confirmation can be determined by analyzing the expression of 
the SL1 marker via polymerase chain reaction (PCR). The ability to sexually differentiate 
between males and females, with both phenotypic and genetic methods, is useful for tests 
in which endocrine-disrupting compounds may masculinize or feminize fish (Balch et al., 
2004), a possible effect of metformin. Adult male and female medaka of the FLFII strain 
can be seen in Figure 1.2 and male and female embryo differentiation under a fluorescence 





Figure 1.2: Sexually mature adult medaka of the female leucophore-free strain cultured in 
the aquatic toxicology laboratory at the University of Ontario Institute of Technology. (A) 





Figure 1.3: Schematics of Japanese medaka developing embryos from Iwamatsu (2004) 
with corresponding embryo photos taken using florescence microscope (Leica DM 2000, 
25X magnification; filter cube: I3; excitation range: blue; filter: BP 450-490; dichromatic 
mirror (green): 510; suppression filter (red): LP 515) both under fluorescence and not. 
Microscope photos were taken in the aquatic toxicology laboratory at the University of 
Ontario Institute of Technology. Leucophores can be seen fluorescing bright yellow in 
males, but absent in females. (A) Stage 23-24 (~48 hpf). (B) 28-29 (~72 hpf). (C) Stage 





1.7 Overall rationale and aim 
 In recent years, there is a growing concern that human pharmaceutical waste 
threatens to disrupt many natural processes of living organisms by the introduction of 
stressors and unnatural contaminants into the environment. One of the most common 
introduced stressors, metformin, is found at relatively high concentrations in the aquatic 
environment, thus the compound’s effects on aquatic life is of the upmost importance. 
Although recently published research has demonstrated effects of metformin on adult fish, 
the experiments only focused on a narrow, specific life stage of the organisms. 
Additionally, the research focused on a single exposure concentration, 40 µg · L-1, which 
is an accurate representation of WWTP effluent, but is higher than the maximum reported 
surface water concentration of 10 µg · L-1 (Niemuth et al., 2015; Scheurer et al., 2012). 
This leaves large gaps in the data, as juvenile effects have not yet been examined, the 
effects of a full life cycle of fish are unknown, and scientists have yet to prove the uptake 
of metformin into fish. Of additional concern is metformin’s bacterial metabolite, 
guanylurea, found in even higher concentrations than its parent compound. To my 
knowledge, there is no information in the literature defining the effects of guanylurea on 
aquatic organisms, leaving a large and concerning gap. This study aims to address these 
gaps by assessing the effects metformin, and its metabolite guanylurea, have on Japanese 
medaka (Oryzias latipes) growth, development, reproduction and sexual differentiation 













Chapter 2: Uptake and early-life stage 
growth studies of metformin and 











 The present study sought to determine the potential for uptake, bioaccumulation, 
and depuration of metformin in early life stage (ELS) Japanese medaka (Oryzias latipes) 
using 14C-metformin. We also exposed fertilized embryos to environmentally relevant, 
waterborne concentrations of metformin, or guanylurea for 28-days post hatch, to examine 
effects of developmental exposure on growth endpoints.  Results demonstrated that both 
embryo and larval stages of medaka were taken up, bioaccumulated, and depurated 
metformin at environmentally relevant concentrations.  Furthermore, we showed that 
chorion hardening (~ 6 hpf), prevented the uptake of metformin by developing embryos. 
We also demonstrated that exposure to both metformin, and guanylurea significantly 
impacted growth metrics in ELS fish. Additionally, we showed that exposure to the primary 
metabolite of metformin, guanylurea, and also caused developmental impacts at exposure 
concentrations an order of magnitude lower than those required by the parent compound to 
exert similar effects.  These results underscore the need for additional studies examining 





 In recent years, the occurrence and fate of pharmaceuticals in the aquatic 
environment has become an emerging issue in aquatic toxicology (Magi et al., 2016). As 
mentioned in section 1.2 Pharmaceuticals in the environment, the majority of human 
pharmaceuticals are taken orally, with gut absorption efficiency ranging from 0-80%, 
however some pass through the body without being absorbed or changed in any way 
(Holford, 2001). Recent studies have found metformin in WWTP effluents at 
concentrations varying from 1 to 47 µg · L-1, and in surface waters at concentrations varying 
from 0.06 to 3 µg · L-1 and is thought to be the highest drug by weight released into the 
aquatic environment with up to 6 tons per year released from individual urban area WWTPs 
(Blair et al., 2013; Crago et al., 2013; Ghoshdastidar et al., 2014; Oosterhuis et al., 2013; 
Scheurer et al., 2012). 
In humans, metformin is the first-line pharmaceutical prescribed to patients with 
type-2 diabetes, polycystic ovary syndrome, and is indicated as a treatment for various 
cancers where insulin resistance is a factor (Tang et al., 2012). Both metformin and 
guanylurea are polar compounds (Table 1.1) and should be extremely mobile in the aquatic 
environment, concerning to organisms living in these aquatic habitats (Scheurer et al., 
2012). Despite the prevalence of metformin in receiving waters, its ecotoxicological 
impacts are largely unknown, including whether or not it is taken up, whether it is stored 
in fish tissue, and the rate at which metformin is depurated. These characteristics are 
important as they can be considered the first step, of many, in improving our understanding 
of the metformin uptake pathway and mode-of-action (MOA) in fish. There has been some 
controversy on whether metformin can partition into tissues, as its log Kow is low at -2.64. 
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To our knowledge, no one has shown whether metformin can be found inside exposed 
aquatic organisms. Proving that metformin does enter the fish would defend the effects 
researchers in the literature have seen metformin elicit on exposed fish thus far.  
 At the present time, it is simply not practical to monitor/test the effects of every 
single human and veterinary pharmaceutical (> 5,000) in use or currently in production on 
non-target aquatic organisms. An optimal research study would include testing the effects 
of both pharmaceuticals and their metabolites on whole life cycles and across multiple life 
cycles. While extremely valuable, these tests are not practical on a large scale because they 
are extremely costly, require a large number of animals, generate large amounts of aquatic 
waste, and take a considerable amount of time (months to years). Fish early-life stage 
(ELS) tests were developed in order to alleviate the monetary, waste, and time concerns, 
while still providing valuable information for compound effects on aquatic organisms.  
 The Organization for Economic Cooperation and Development (OECD) 210 
outlines the value of ELS testing, while laying out a method for conducting an acceptable 
test. These tests are intended to define the lethal and sub-lethal effects of chemicals on the 
sensitive early life stages of the species being tested (OECD 210, 2013). Such tests produce 
valuable information that can be used to the estimation of more chronic effects of the 
chemical on organisms. ELS testing is currently the most frequently used bioassay for 
predicting chronic effects (Volz et al., 2011). These tests typically last 1-3 months, in this 
case 28 days, and focus on the survival and growth of the organism. However, tests may 
be supplemented with behavioral and developmental monitoring, and coupled with 
endpoints analyzing genetic and metabolomic changes may be used to investigate the 
chemical mode of action of various compounds. For clarity, the research in this portion of 
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the dissertation used the OECD 210 as a basic framework for the experimental methods, 





 The objectives of this experiment were to: 
 Determine if metformin can be taken up, bio-accumulated, and depurated by 
exposed Japanese medaka (Oryzias latipes) at embryonic and larval stages. 
 Asses the effects (length, wet weight, and condition factor) of a range of 
environmentally relevant concentrations of metformin and guanylurea on 
developing medaka via a 28 day ELS test.  
 Assess if male and female medaka exposed to a range of environmentally relevant 
concentrations of metformin and guanylurea are effected (length, wet weight and 





 Ho1: Embryonic and larval medaka exposed to C
14-metformin for any amount of 
time will not take up C14-metformin, and thus will not accumulate or depurate out the 
compound. 
 Ho2: Medaka exposed to various concentrations of metformin from embryo through 
28 days will not have significant differences in length, wet weight, or condition factor when 
compared to control fish.  
 Ho3: There are no differences in length and weight of female and male medaka 
exposed to metformin from embryo through 28 days.  
 Ho4: Medaka exposed to various concentrations of guanylurea from embryo through 
28 days will not have significant differences in length or weight when compared to control 
fish.  
 Ho5: There are no differences in length and weight of female and male medaka 




2.3 Materials and methods 
2.3.1 Chemicals 
 Metformin hydrochloride (1,1-dimethylbiguanideine hydrochloride; CAS# 1115-
70-4) was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada). 
Guanylurea (CAS# 141-83-3) was purchased from Sigma-Aldrich (Oakville, Ontario, 
Canada) and methanol (CAS# 67-56-1) from ACP Chemicals Inc. (Montreal, Quebec, 
Canada). 14C-Metformin (Metformin [biguanido-14C] HCL ARC 1738A; specific activity: 
100 mCi/mmol) was purchased from American Radiolabeled Chemicals Inc. (St. Louis, 
Missouri, USA) and scintillation fluid (Ultima Gold F, Part# 601371) was purchased from 
Perkin Elmer (Akron, Ohio, USA). 
2.3.2 Animal care 
Adult Japanese medaka (FLFII strain) were obtained from the National Institute for 
Basic Biology (Okazaki, Japan), and housed at the University of Ontario Institute Of 
Technology (Oshawa, ON, Canada).  Animals were housed in three, 70 liter tanks, each 
containing 40 adult fish in optimal breeding ratios of two males to three females.  All 
embryos used in the present study were obtained by gently stripping eggs from each gravid 
female with a gloved finger. Debris was removed from embryos by gently rolling them on 
clean paper towel.  Embryos were pooled, placed in rearing solution (0.1% NaCl, 0.0163% 
MgSO4·7H2O, 0.004% CaCl2·H2O, 0.003% KCl, and 0.0001% methylene blue, prepared 
in de-ionized (DI) water), and kept in a climate controlled room (27°C) for 1-hour to assess 




2.3.3 Radiolabeled metformin assays 
2.3.3a Embryo/chorion preparation 
 Japanese medaka embryos were collected from the laboratory culture of Japanese 
medaka as previously mentioned in 2.3.2 Animal care. Viable embryos were split into 2 
groups: (1) pre-chorion hardening and (2) post-chorion hardening. There were 3 replicates 
per treatment, with 60 embryos per replicate.  Both treatments were exposed to 10 µg · L-
1 (6.05 E-5 mM) 14C-metformin for 24-h, with exposure beginning either pre-chorion 
hardening (< 6 hours post fertilization (hpf)), or post-chorion hardening (24-hpf). Embryos 
were housed in 6-well plates containing 5-mL of test solution per well.  In order to prepare 
the 6.05 E-5 mM 14C-metformin treatment solution, a stock of 0.01 mM was prepared by 
mixing 10 µl of the 1-mM master stock with 990 µl of clean lab water. From this stock, the 
treatment solutions were prepared by mixing 544.5 µl of the 0.01 mM stock with 89.45 mL 
of clean lab water.  
 Each treatment group was exposed for 24 h. After this exposure period, embryos 
were rinsed 5 times with 5 ml of clean lab water. Each replicate was then transferred to a 
separate scintillation vial containing 5-ml of scintillation fluid (in which the embryos were 
quickly sacrificed).  A scintillation counter (Perkin Elmer Tri-Carb 2800TR) was used to 
quantify 14C-metformin in the embryos using the methods described in the 2.3.4d 
Metformin determination section below.  
2.3.3b Larval preparation 
 For the larval portion of the study, embryos were collected in the same manner as 
previously described in 2.3.2 Animal care. Embryos were separated by sex using a 
fluorescent (Leica DM 2000) microscope 118 hpf and were kept separate for the remainder 
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of the experiment. Only male medaka of the FLFII strain contain leucophores, which 
fluoresce under a fluorescent microscope. Male and female embryos 118 hpf are shown in 
Figure 2.1. Embryos were then kept separate for the remainder of the experiment to assess 
if there was a difference in metformin uptake between sexes. Embryos were monitored 
using a dissecting scope in the same manner as the ELS studies, and once hatched, were 
exposed to 10 µg · L-1 (6.05 E-5 mM) 14C-metformin for 24 h to compare sex based uptake 
differences. To determine uptake steady state, an additional study was run without sex 
separation. Similar to the previous study, larvae were exposed to 10 µg · L-1 (6.05 E-5 mM) 
14C-metformin for 24 h or 168 h (7 days) to analyze accumulation. Each treatment had 4 
replicates with 20 larvae per replicate for both experiments. After the exposure periods, 
larvae were rinsed 5 times with 5 mL of clean lab water before being placed in a vial of 
scintillation fluid and analyzed for radioactivity on the scintillation counter; larvae were 





Figure 2.1. Embryo (~118 hpf) photos taken using florescence microscope (Leica DM 
2000, 25X magnification; filter cube: I3; excitation range: blue; filter: BP 450-490; 
dichromatic mirror (green): 510; suppression filter (red): LP 515) both under fluorescence 
and normal light. Microscope photos were taken in the aquatic toxicology laboratory at the 
University of Ontario Institute of Technology. Leucophores can be seen fluorescing bright 




2.3.3c Depuration study 
 To examine the rate at which larval medaka can depurate metformin, we exposed 
embryos (< 6 hpf) to 10 µg · L-1 4C-metformin for 24 hours, with a sub-sampling time-
point at test hour 8.  Each treatment consisted of three replicates, containing 60 embryos 
per replicate.  Following the metformin exposures, embryos were rinsed 5 times with 5 mL 
of clean lab water before being transferred to clean water for the remainder of the assay.  
The remaining body burden of 14C-metformin was characterized via scintillation counter 
(again, methods described in more detail in 2.3.4d Metformin Determination section 
below). 
 The assay was repeated with newly hatched larval medaka, using the same 
concentrations of 14C-metformin, and sub-sampling/quantification methods described in 
the embryo assay. An additional sub-sampling time-point at 4-hours was added to improve 
the resolution of the assay.  The 24-hour exposure to metformin was initiated immediately 
following hatch with, once again, three replicates per treatment, each containing 15 larvae.   
2.3.4 Metformin and guanylurea exposure assays 
2.3.4a Early-life stage studies 
 Medaka embryos were collected as previously described in 2.3.2 Animal care. 
Embryos were separated by sex 118 h post-fertilization and were then kept separate for the 
remainder of the experiment to determine whether or not effects of exposure were 
dependent on sex. Embryos were randomly assigned to a treatment containing one of five 
concentrations of waterborne metformin (1.0, 3.2, 10, 32 and 100 µg · L-1), or a solvent 
control treatment.  Embryos were maintained in plastic petri dishes (Fisher Scientific, 
60x15 mm), each containing 20-mL of the assigned treatment solution.  Four replicates per 
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concentration (per sex) were used, with each replicate containing 30 eggs.  Test solutions 
were renewed daily, and were prepared using a 10,000 mg · L-1 metformin master stock.  
As the master stock concentration exceeded the solubility of metformin in water, it was 
prepared using methanol (MeOH) as the initial carrier solvent, and then further diluted in 
rearing solution to achieve target concentrations. The MeOH carrier was kept at 0.01% for 
all solutions (including the solvent control) for the remainder of the study. For guanylurea 
exposures, a 100 mg · L-1 master stock (in deionized (DI) water) was used to prepare 
treatment solutions of 1.0, 3.2, 10, 32 and 100 ng · L-1 in rearing solution. The master stock 
did not exceed guanylurea’s solubility limits in water, and therefore no exposure to MeOH 
occurred in any of the guanylurea studies.  
All embryos were exposed to their assigned treatment solutions in a temperature 
controlled room (27 ˚C) and a 16:8 (light: dark) period with 0.5 hours each of dawn and 
dusk included in the light phase. Embryos were monitored under a dissecting 
stereomicroscope LEICA EZ4D (20x magnification) daily, using the developmental 
staging methods described by Iwamatsu (2004) and Wakamatsu (2003). Occurrence of 
developmental abnormalities, mortality, hatch success, and time-to-hatch were recorded 
daily. 
 Upon hatch, larval fish were transferred to 1-L plastic trays that corresponded with 
their exposure concentration and replicate number for the remainder of the 28-day study. 
Target waterborne concentrations of metformin (1.0, 3.2, 10, 32 and 100 µg · L-1) and 
guanylurea (1.0, 3.2, 10, 32 and 100 ng · L-1) were achieved using a flow-through system 
(Watson-Marlow 200 Series 16-channel peristaltic pump) that delivered stock 
concentrations from 1-L brown bottles in the appropriate volumes. Stocks of metformin 
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were prepared in clean water from a 10,000 mg · L-1 master stock prepared in MeOH 
(MeOH was 0.01% in all solutions), and a 1,000 mg · L-1 master stock (prepared in DI) for 
guanylurea. Exposure solution volume exchange insured 95% molecular turnover in 24 
hours in each exposure tank. Larval medaka were fed 15 mL of live concentrated Premium 
Grade Brine Shrimp (Brine Shrimp Direct, San Francisco, California) twice per day for the 
entirety of the 28-day exposure. The bottom of the trays were vacuumed once per day to 
rid them of waste and leftover brine shrimp.   
2.3.4b Biological endpoints 
Three sub-sampling events occurred during the 28-day growth study; on days 7, 14, 
and 28 (test termination). On day 7, four fish were sub-sampled from each of the four 
replicate trays (per sex) maintained in the flow-through system. Five fish per replicate (per 
sex) were sub-sampled on day 14, with all remaining fish were collected and sampled at 
test-termination on day 28.  At each sampling point (day 7, 14 and 28), larval fish were 
euthanized in water containing tricaine methane-sulphonate (200 mg · L-1), buffered with 
sodium bicarbonate (400 mg · L-1). Individual fish length was measured using a digital 
caliper, and wet weight was measured using a Metler Toledo MX5 microbalance. At each 
time point, the individual lengths and weights of subsampled fish were averaged to find a 
replicate mean.  Replicate means were used for all statistical analyses regarding growth 
endpoints (n = 4 trays). Condition factor was calculated via the following medaka 
established equation, weight (g) x 105/length (mm)3 (Brooks et al., 2003). 
2.3.4c Statistical analysis 
 All data were analyzed using SigmaPlot (Systat Software Inc.) unless otherwise 
specified. Normality of all data was confirmed using a Shapiro-Wilk test prior to 
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subsequent statistical analysis. The effects of chorion hardening on 14C-metformin uptake 
were determined using a 1-way ANOVA.  Effects of sex on size (length, weight, and 
condition factor) of 28-dph fish were assessed using a 2-factor ANOVA, followed by a 
Bonferroni post hoc.  Similarly, a 2-factor ANOVA was used to determine the effects of 
sex on larval uptake of 14C-metformin over time.  The time required for larvae to depurate 
50% of 14C-metformin (ET50; with a 95% confidence interval) was calculated by 
performing an inverse prediction (50%) of the exponential depuration curve, with JMP 
software (Version 13, SAS Institute).  Treatment effects on growth (using both length, and 
weight) over time (dph) were determined using a 2-factor ANOVA (with exposure 
concentration and time as factors), followed by a Tukey’s post hoc test. An α of 0.05 was 
used to determine statistical significance for all tests.  
2.3.4d Metformin determination 
 The concentration of 14C-metformin in tissue samples was determined via 
scintillation counter, which detects ionizing radiation emitted from 14C-metformin via 
excitation of incident radiation in the scintillation fluid (Perkin Elmer, Akron, Ohio, USA). 
A 10-point quench curve was performed to determine counting efficiency, with light pulses 
measured in counts per minute (cpm). The established quench curve used the relationship 
between counting efficiency and quench-indicating parameters to convert the measured 
counts per minute (cpm) to disintegrations per minute (dpm).  Dpm were then divided by 
the rate constant (2.22 x 1012 dpm/Ci) to obtain curies (Ci). The calculated Ci was then 
divided by the specific activity of 14C-metformin (1 Ci/mmol) to convert Ci to mmoles (all 
radiochemical equations found on Perkin Elmer Radiochemical Calculations, 
www.perkinelmer.com).  Background readings from the scintillation counter (determined 
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as the average of 3 blanks containing only scintillation fluid) were subtracted from the 
radio-labeled sample readings.   
 Determinations of waterborne metformin and guanylurea concentrations in the ELS 
studies were performed using a Shimadzu 10A liquid chromatograph coupled with an AB 
Sciex Qtrap 5500 mass spectrometer, at the Water Quality Centre at Trent University 
(Peterborough, Ontario, CA).  Metformin and guanylurea were below the method detection 
limit (MDL; 0.25 µg · L-1) in all control samples, and all guanylurea treatment samples 
(Table 2.2). Water samples were collected twice for chemical analysis during each ELS 
study, once at the beginning and once at the end, by collecting 50 ml of solution from each 
tank into 60 mL polypropylene copolymer bottles and storing at 4˚C in the dark until 




Table 2.1. Nominal and mean concentrations (± standard error) of metformin as measured 
by liquid chromatography-mass spectrometry.  
Nominal metformin 
(µg·L-1) 
Mean measured metformin 
Males (µg·L-1; SE) 
Mean measured metformin 
females (µg·L-1; SE) 
Solvent control < 0.25 <0.25 
1.0 0.94 (0.131) 0.96 (0.062) 
3.2 3.18 (0.441) 3.53 (0.491) 
10 11.9 (1.35) 11.1 (1.38) 
32 36.5 (3.59) 34.1 (1.87) 







2.4.1 Metformin uptake and depuration 
 Embryos exposed to 10 µg · L-1 (6.05 E-5 mM) 14C-metformin prior to chorion 
hardening (< 6 h post-fertilization) had significantly (DF = 5, F = 267.13, p < 0.001) more 
14C-metformin compared to embryos exposed post-chorion hardening (24-hpf), which did 
not appear to take up any 14C-metformin (concentrations were below the MDL; Figure 2.2). 
Consequently, all instances where embryos are discussed in the uptake and depuration 
results and discussion sections will hereafter refer to embryos exposed < 6-hpf.   The mean 
(± 1 SE) amount of 14C-metformin measured in medaka embryos was 0.08 ± 0.01 µg/egg. 
Following transfer to clean water medaka embryos rapidly excreted 14C-metformin, with 
body-burdens of 14C-metformin returning to background levels (below the MDL) within 
the 24-hour depuration period (Figure 2.3). The calculated ET50 for embryos is 8.79 hours 
(95% Confidence Intervals: 3.91, 13.68). The embryos depurated much more rapidly than 
expected, resulting in a very wide confidence interval, thus we were not able to generate a 





Figure 2.2: Amount of 14C-metformin uptake by Japanese medaka embryos exposed to 10 
µg · L-1 (6.05 E-5 mM) 14C-metformin for 24 hours. Pre-chorion hardening represents 
embryos exposed within 6 hours of fertilization, and hardened chorion hardening 
represents embryos exposed 24 hours post fertilization (n = 3, with 60 embryos/replicate). 





Figure 2.3: Depuration curve representing the amount of 14C-metformin in Japanese 
medaka embryos exposed to 10 µg · L-1 14C-metformin for 24 hours, followed by clean lab 
water depuration periods for up to 24 hours (n=60 embryos/day, r2 = 0.98). Solid circles 




 Body-burdens of 14C-metformin measured in larvae exposed to 10 µg · L-1 14C-
metformin for 24-h, and 168-h were not significantly different from one another (DF = 1, 
F = 1.66, p = 0.267, Figure 2.4), indicating larvae reached steady-state rather quickly.  On 
average, each larval fish contained 0.78 ± 0.03 µg of 14C-metformin/larvae, with no 
significant differences indicated between sexes (ANOVA DF = 1, F = 0.843, p = 0.410), 
corresponding to an approximate body burden of 3.12 µg/mg body weight . Therefore, 
sexes were not separated for the remainder of the analyses. Following transfer to clean 
water, larval fish rapidly excreted 14C-metformin, with body-burdens of 14C-metformin 
returning to background levels (below the MDL) within the 24-hour depuration period 
(Figure 2.6). The calculated ET50 for larval fish was 4.88 hours (95% Confidence 





Figure 2.4: Comparison in the amount of 14C-metformin found in 24 hr post hatch Japanese 
medaka larvae exposed to 10 µg · L-1 14C-metformin for 24 hr and 168 hr (n = 20 





Figure 2.5: Depuration curve representing the amount of 14C-metformin in Japanese 
medaka larvae exposed to 10 µg · L-1 14C-metformin for 24 hours, followed by clean lab 
water depuration periods for up to 24 hours (n = 15 fish/day, r2 = 0.99). Solid circles 




2.4.2 Effects of metformin on larval growth 
 There were no significant differences in percent mortality (ANOVA DF = 5, F = 
0.951, p = 0.458), hatch success (ANOVA DF = 5, F = 0.591, p = 0.707) or time-to-hatch 
(ANOVA DF = 5, F = 1.78, p = 0.114) in medaka embryos exposed to metformin, relative 
to controls (Table 2.4). Similarly, no developmental abnormalities were seen in any control 
or exposed embryos (apart from reduced size).  Sex did not significantly affect the size 
(weight or length) of 28-dph fish in the present study (length: 2-way ANOVA DF = 5, F = 
0.915, p = 0.471; length: 2-way ANOVA DF = 5, F = 1.45, p = 0.206), and therefore growth 
metrics between sexes were pooled for the remainder of the analyses.  
 Metformin exposure significantly affected fish weight over the course of the 28-
day study, with significantly reduced mean wet weights of larvae observed at the first 
sampling time-point (7-dph) in the 100 µg · L-1 metformin (Figure 2.7A) treatment. 
Similarly, the length of developing larvae was affected by exposure to metformin. No 
significant effects of treatment on fish length were indicated at the 7-dph sampling time-
point (Figure 2.7B).  However, significant treatment effects on both mean wet weight and 
length were observed by 14-dph (Figure 2.7).  At 28-dph, mean wet weight was 
significantly reduced in all exposure concentrations (DF = 17, F = 322, p < 0.001; Figure 
2.7B, Table 2.4), while exposure to metformin concentrations ≥ 3.2 µg · L-1 significantly 
decreased the mean length of medaka (DF = 17, F = 902, p < 0.001; Figure 2.7B; Table 
2.4) when compared with controls. However, condition factor (weight (g) x 105/length 
(mm)3) was unaffected by metformin exposure (ANOVA DF = 5, F = 1.62, p = 0.152).  
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Table 2.2. Percent larval mortality, percent hatch success, and mean time to hatch (± 
standard error) for medaka exposed to metformin for a 28 day early life stage study. 
Concentration 
(µg·L-1) 




Time to hatch  
(days, ±SE) 
Solvent control 11.7 (0.111) 87.5 (0.921) 8.91 (0.041) 
1.0 11.7 (0.167) 85.8 (0.921) 8.78 (0.042) 
3.2 13.3 (0.143) 87.9 (0.962) 8.63 (0.043) 
10 11.7 (0.167) 92.5 (0.674) 8.78 (0.042) 
32 16.7 (0.164) 89.6 (0.989) 8.83 (0.042) 





Figure 2.6: Mean wet weight (A) and length (B) of 28 day old Japanese medaka (± SE) by day and metformin treatment 
concentration (day 7 n = 4 (with 8 fish/replicate), day 14 n = 4 (with 10 fish/replicate), day 28 n = 4 (with 40 fish/replicate). 






Table 2.3. Japanese medaka wet weight and length as percent control for each metformin exposure concentration. Values reflect 
means and (± standard error). Values with an alphabetical superscript in common are not significantly different p < 0.05.  
  Metformin (µg·L-1)    
 1 3.2 10 32 100 
% control      
Wet weight 77.6(0.017)a 73.4(0.001)a 66.6(0.008)b 65.5(0.013)b 64.5(0.013)b 
Length 99.6(0.009)a 95.6(0.024)b 96.4(0.007)ab 85.3(0.016)c 81.0(0.005)d 
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2.4.3 Effects of guanylurea on larval growth 
 No significant differences in embryo mortality (ANOVA DF = 5, F = 0.423, p = 
0.831), hatch success (ANOVA DF = 5, F = 0.401,p = 0.846), or time-to-hatch (ANOVA 
DF = 5, F = 1.914, p = 0.089) were observed in any of the guanylurea treatment 
concentrations, when compared with controls (Table 2.5).  Similarly, no developmental 
abnormalities were observed in control or guanylurea-exposed embryos (apart from 
reduced size). Again, sex did not significantly affect the size (weight or length) of 28-dph 
fish in the present study (weight: 2-way ANOVA DF = 5, F = 0.464, p = 0.803; length: 2-
way ANOVA DF = 5, F = 0.266, p = 0.931), and therefore growth metrics were not 
separated by sex for the remainder of the analyses.  
Developmental exposure to guanylurea (through 28-dph) led to significant 
differences in wet weight and length of medaka (Figure 2.10). Specifically, significant 
differences in fish size (both wet weight and length) were not apparent at the 7, or 14-dph 
time points (p > 0.05). However, 28-dph fish from all guanylurea exposure concentrations 
weighed significantly less (DF = 17, F = 1626, p = < 0.001); Figure 2.10A; Table 2.5), and 
were significantly shorter (DF = 17, F = 316, p < 0.001); Figure 2.10B; Table 2.5), when 
compared with control fish. However, condition factor (weight (g) x 105/length (mm)3) was 




Table 2.4. Percent larval mortality, percent hatch success, and mean time to hatch (± 
standard error) for medaka exposed to guanylurea for a 28 day early life stage study. 
Concentration 
(ng·L-1) 




Time to hatch  
(days, ±SE) 
Control 15.0 (0.147) 87.5 (0.921) 8.92 (0.043) 
1.0 16.7 (0.189) 85.8 (0.921) 8.78 (0.042) 
3.2 18.3 (0.252) 87.1 (0.854) 8.77 (0.046) 
10 15.0 (0.309) 90.8 (0.491) 8.81 (0.044) 
32 18.3 (0.156) 87.9 (0.801) 8.77 (0.043) 






Figure 2.7: Mean wet weight (A) and length (B) of 28 day old Japanese medaka (± SE) by day and guanylurea treatment 
concentration (day 7 n = 4 (with 8 fish/replicate), day 14 n = 4 (with 10 fish/replicate), day 28 n = 4 (with 40 fish/replicate). 





Table 2.5. Japanese medaka wet weight and length as percent control for each guanylurea exposure concentration. Values reflect 
means and (± standard error). Values with an alphabetical superscript in common are not significantly different p < 0.05. 
  Guanylurea (ng·L-1)    
 1 3.2 10 32 100 
% control      
Wet weight 87.4(0.010)a 83.2(0.009)ab 77.0(0.010)ab 68.8(0.007)ab 75.6(0.019)b 






 These results demonstrated that the common water contaminant, metformin, and its 
metabolite, guanylurea, have measurable impacts on the growth of early life-stage Japanese 
medaka. One concern not previously addressed in studies of metformin is whether or not 
uptake and accumulation occurs in fish. Because of metformin’s low log Kow (-2.64), it 
has generally been thought that the compound would not readily cross the gills into the 
organism (US EPA, 2012). This is the first study to investigate and show that metformin 
can be taken up and transiently stored in the embryo and larval fish. This is an important 
finding, as it provides confirmation that the documented effects of metformin in fish are 
likely due to compound uptake. Due to the similar chemical structure of guanylurea, it is 
plausible to assume that it also can be taken up by fish, thus providing further insight into 
the effects of metformin’s metabolite on larval growth. 
Another interesting finding from our study was the metformin uptake and 
accumulation in pre-chorion hardened eggs compared to post-chorion hardened eggs. We 
also showed that when embryos were exposed to 14C-metformin before the chorion 
hardened, followed by a short 24 h depuration, all of the detectable metformin was 
depurated out of the embryo. Similarly, this has been observed in zebrafish exposed to 
various xenobiotics (Fischer et al., 2013). Researchers found that an ATP-binding cassette 
(ABC) transporter, specifically Abcb4, was successful in transporting xenobiotics out of 
the developing embryo, thus protecting the embryos from toxic chemicals dissolved in 
water (Fischer et al., 2013).  
Metformin and guanylurea exposure over 28-days resulted in stunted growth in 
both male and female medaka at environmentally relevant concentrations, with significant 
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concentrations seen as low as 3.2 µg · L-1 metformin and 1.0 ng · L-1 guanylurea. This 
suggests that exposure to both compounds may potentially lead to population-level effects, 
as insufficient body size can pose both reproductive and survival problems in fish. Pollock 
et al. (2008) observed significantly less reproductive success for smaller male fathead-
minnow (FHM) mating-pairs. Additionally, significantly fewer cumulative clutches with 
significantly smaller clutch sizes were laid per mating pair in FHM exposed to 40 µg · L-1 
metformin when compared to controls (Niemuth and Klaper, 2016). The implication of 
stunted growth in these early life stages, as seen in our study could lead to broader 
reproductive problems at the population scale, as seen in the aforementioned FHM studies.  
To the best of our knowledge, this is the first study to address the effects of broad, 
environmentally relevant concentrations of metformin and guanylurea on the early life 
stages of fish. Although several studies have documented the occurrence of metformin in 
WWTP effluent at concentrations varying from 1 µg · L-1 to 47 µg · L-1, and in surface 
waters at concentrations varying from 0.06 µg · L-1 to 3 µg · L-1 (Blair et al., 2013; 
Ghoshdastidar et al., 2014; Niemuth et al., 2015; Oosterhuis et al., 2013; Scheurer et al., 
2012), very few have looked at guanylurea. One study specifically found that the removal 
of metformin from German wastewater treatment plants was correlated to the formation of 
guanylurea, found at concentrations of 0.22-1.2 µg · L-1 and 0.1-28 µg · L-1, respectively 
(Scheurer et al., 2012). We are now able to confirm that the environmentally relevant 
concentrations of metformin and guanylurea can cause detectable effects, especially at 
concentrations far below the range measured for guanylurea in surface waters. 
It remains unclear what underlying mechanism(s) are involved in the measured 
growth effects of metformin and guanylurea in Japanese medaka. However, because 
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metformin acts primarily by inhibiting complex I of the mitochondrial transport chain, it 
may lead to a decrease in available ATP, which promotes the activation of adenosine 
monophosphate kinase (AMPK) involved in regulating cell metabolism (Crago et al., 
2016; Gong et al., 2012; Hawley et al., 2010). The activation of AMPK then inhibits acetyl-
CoA-carboxylase, which in turn inhibits fatty acid synthesis while promoting fatty acid β-
oxidation (Gong et al., 2012). This likely results in fatty acid dysregulation leading to 
disrupted energy stores, which could negatively affect growth. Unfortunately, nothing is 
known at this time about the mode of action of guanylurea in living organisms.  
Overall findings from this chapter of the dissertation demonstrate the need for 
further research into the effects of metformin and its metablite guanylurea on non-target 
aquatic organisms. It is apparent from the research presented here that low, 
environmentally relevant concentrations of both compounds cause a detectable decrease in 
the growth of Japanese medaka. Future studies should investigate changes in gene 
expression and metabolism in response to metformin and guanylurea exposure, particularly 















Chapter 3: Metabolomics and gene 
expression in early-life stage Japanese 
medaka (Oryzias latipes) exposed to 









 Environmentally relevant concentrations of metformin, and its metabolite 
guanylurea, have been shown to inhibit the growth of developing Japanese medaka 
(Oryzias latipes) exposed to the compounds from embryo through 28 days post hatch. In 
this chapter, metabolomics was used to identify cellular pathways disrupted by metformin 
and guanylurea exposure in medaka larvae exposed from embryo through 28 days post 
hatch. Results were further applied to select genes of interest for RT-qPCR analyses. 
Several metabolite abundances were altered by the exposure of medaka to 3.2 µg · L-1 
metformin and 1.0 ng · L-1 guanylurea, which included metabolites associated with cellular 
energetics, fatty acid synthesis and metabolism, and polyamine synthesis. Expression of 
critical genes involved in lipid metabolism were also significantly affected. Collectively, 
these results suggest that environmentally relevant concentrations of metformin and 





Chapter 2 showed that both metformin and guanylurea have significant impacts on 
the growth of Japanese medaka (Oryzias latipes) at environmentally relevant 
concentrations. Medaka wet weight and length were significantly affected by exposures to 
metformin at concentrations as low as 3.2 µg · L-1 (Ussery et al., 2018). Additionally, we 
demonstrate effects on fish size at waterborne guanylurea concentrations as low as 1.0 ng 
· L-1, over an order of magnitude lower than the metformin concentrations required to 
evoke similar effects and about 30,000 times lower than the concentrations measured in 
German surface waters (Scheurer et al., 2012; Ussery et al., 2018).  
As previously mentioned, ELS testing is currently the most frequently used 
bioassay for predicting chronic effects of compounds on fish (Volz et al., 2011). ELS 
studies typically focus on the survival and growth of the organism, however tests may be 
supplemented with endpoints analyzing genetic and metabolomic changes to investigate 
the chemical mode of action of compounds. Metabolome analysis is used to study 
concentrations of organic, low molecular weight metabolites in tissues (Bridges et al., 
2016; Nishiumi et al., 2014). To our knowledge, there is no prior information in the 
literature outlining the genetic or metabolomic effects of metformin and guanylurea in 
early-life stage fish. 
 The metabolome represents the final endpoint of the ‘omics cascade 
(genomics>transcriptomics>proteomics>metabolomics), leading it to be the closest point 
in the cascade related to the organism’s phenotype (Nishiumi et al., 2014). Metabolite 
profiles are a summary of upstream ‘omics profiles, specifically the enzymatic activities of 
various proteins, and metabolome analysis might be able to detect subtle changes in 
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metabolic pathways and deviations from homeostasis before potential phenotypic changes 
occur (Nambiar et al., 2010; Rochfort, 2005). Thus, the metabolite profile of a cell is more 
likely to represent the cell’s current status than its DNA, RNA, or protein profile (Nishiumi 
et al., 2014). Additionally, gene expression work is a useful tool to use in combination with 
metabolomics data, therefore, this study aims to address how exposure to environmentally 
relevant concentrations of metformin and guanylurea affect both the metabolome and gene 
expression of Japanese medaka, with hopes that this could help explain the stunted growth 





 The objectives of this experiment were to: 
 Employ metabolomics as a screening method to identify potential disruptions in 
normal cellular metabolism/homeostasis in Japanese medaka exposed to 
environmentally relevant concentrations of metformin and guanylurea after a 28 
day ELS study. 
 Based on metabolomics results, choose specific genes that may be differentially 






 Ho1: The metabolome of Japanese medaka will not be altered following 28-day 
exposure to environmentally relevant concentrations of metformin and guanylurea.  
 Ho2: Medaka exposure to environmentally relevant concentrations of metformin 




3.3 Materials and methods 
 The analysis performed in Chapter 3 are a continuation of the ELS studies reported 
on in Chapter 2. The experimental lowest observed effect concentrations (LOEC) were 
used for each experimental exposure: 3.2 µg · L-1 metformin and 1.0 ng · L-1 guanylurea, 
and were each compared to their respective controls. Subsamples of larval fish were 
transferred to clean microcentrifuge tubes and flash frozen in liquid nitrogen. Eight 
biological replicates containing 20 mg of tissue (~2 larvae) were analyzed for each of the 
treatments. 
3.3.1 Metabolite analysis  
 Larvae were homogenized in cold 2:5:2 chloroform:methanol:Mili-QTM water 
solution with a motorized pestle and centrifuged at 14,000 rotations per minute (rpm) at 
4˚C for 8 minutes. The supernatant was removed and transferred to a clean microcentrifuge 
tube and spiked with 10 µL of 150 mg/mL D-27 Myristate internal standard (IS), followed 
by evaporation under a gentle stream of nitrogen. Evaporated samples were derivatized 
with 50 µL of 15 mg · L-1 methoxyamine in pyridine solution, vortexed, then heated at 
50˚C for 30 minutes. A second derivatization step with the addition of 50 µL of N-methyl-
N-trimethylsilyltri-fluoroacetamide (MSTFA) with 1% trimethylchlorosilane (TMCS), 
vortexed, and again heated at 70˚C for 30 minutes. After 30 minutes, samples were 
analyzed by gas chromatography-mass spectrometry (GC-MS; Agilent 6890 GC and 5973 
MS).  
 To identify the metabolites, the Agilent Fiehn Retention Time Locking Library 
(Agilent part # G1676-90000) was used according to the manufacturer’s recommendations. 
Chromatographic (.D) files were processed using the Automated Mass Spectral 
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Deconvolution & Identification System (AMDIS; National Institute of Standards and 
Technology, Gaithersburg, Maryland), then submitted to the Agilent Fiehn library to 
generate semi-quantitative relative response factors ratios against the response of the IS. A 
suite of fatty acid methyl ester standards were injected into every 5th sample (n=3) to 
provide data for the AMDIS Retention Index library used to track slight variations in 
predicted metabolite retention times.  
3.3.2 Measures of gene expression 
 Subsamples of two larval fish per treatment from ELS studies and transferred to 
clean microcentrifuge tubes and flash frozen in liquid nitrogen. Again, experimental 
LOECs were used for each exposure: 3.2 µg · L-1 metformin and 1.0 ng · L-1 guanylurea, 
and compared to their respective controls. Larvae were homogenized in 250 µL of TRI 
reagent (PureZOLTM RNA Isolation Reagent, Bio-Rad) using a hand held homogenizer. 
Once homogenized, an additional 250 µL of TRI reagent was added to each sample. 
Samples were vortexed, then centrifuged at 12,000 g for 10 minutes at 4˚C. Post 
centrifugation, the clear middle layer was transferred to a new 1.5 mL RNAase/DNAase 
free Eppendorf tube, and was allowed to stand for 5 minutes at room temperature. 
Afterward, 150 µL of chloroform was added to each sample and gently inverted repeatedly 
to mix. The samples were left to stand at room temperature to allow for visible separation 
of the layers (~ 5 minutes). Once separated, samples were centrifuged at 12,000 g for 15 
minutes at 4˚C resulting in three phases: a protein layer at the bottom, a middle interface 
containing DNA, and a colorless upper aqueous phase containing RNA. The upper aqueous 
RNA phase was transferred to a fresh 1.5 mL Eppendorf tube and 200 µL of isopropanol 
was added, vortexed, and left to stand for 5 minutes. After 5 minutes, the samples were 
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centrifuged at 12,000 g for 10 minutes at 4˚C. Post centrifugation, the supernatant was 
discarded and the RNA pellet was washed with 500 µL of 75% EtOH, vortexed and 
centrifuged at 7600 g for 5 minutes at 4˚C. The excess EtOH was removed, leaving the 
pellet undisturbed. The RNA pellet was then dissolved in 50 µL of Tris-EDTA (TE) buffer 
and stored at -20˚C until use.  
 RNA concentration and purity was determined using a 0.2 mm TrayCell coupled 
with a Cary 50 Bio UV-Visible Spectrophotometer. Samples were analyzed at 260 nm and 
a 2000 factor, with factor = sample specific factor x virtual dilution factor (ssRNA = 40 x 
50, respectively). The Cary was zeroed using 2 µL of TE buffer. Then, 2 µL of each sample 
was run in duplicate, cleaning with EtOH between each sample and replicate. Samples 
were deemed acceptable if the purity ratio (OD260/280) was greater than 1.7 and the RNA 
concentration was between 50 ng · µL-1  (min) – 500 ng · µL-1  (max). 
 RNA quality was determined using Experion RNA StdSens kits, following the 
manufacturer’s protocol (BioRad). Electrodes were cleaned/rinsed by pipetting 800 µL of 
electrode cleaner into any middle well of the electrode cleaning chip, and placed into the 
Experion for 2 minutes. The chip was removed, and 800 µL of diethyl pyrocarbonate 
(DEPC)-H2O was pipetted into the DEPC chip, and left in the Experion for 5 minutes. The 
Experion was allowed to air dry for about a minute after the chip was removed, then the 
cleaning procedure was repeated once more. The filtered gel was prepared by pipetting 600 
µL of gel stain into the filter tube and centrifuging at 1500 g for 10 minutes. The gel stain 
was prepared by adding 1 µL of stain to 65 µL of filtered gel in a 1.5 mL tube and vortexing. 
RNA ladder and samples were prepared by pipetting 2 µL of ladder/samples into 0.2 mL 
PCR tubes, followed by a 2 minute denaturing step at 70˚C, then left for 5 minutes on ice. 
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The RNA StdSens chip was primed with 9 µL of gel stain into the gel priming well, then 
inserted into the Experion priming station and primed using setting B1. After priming, the 
chip was loaded in the following order: 9 µL of filtered gel, 5 µL of loading buffer into the 
13 wells, and 1 µL of sample plus ladder into the wells. The chip was then placed in the 
Experion vortex station for 1 minute, then run on the Experion using the Experion RNA 
StdSens Assay. RNA Quality was reported via RNA quality indicator (RQI). Samples with 
a value of >7 were deemed acceptable for use in RT-qPCR work.  
 Genes chosen for RT-qPCR analysis were selected based on literature availability 
and their relevance to the metabolomics data sets. Medaka genome sequences were found 
in the national center for biotechnology information (NCBI) database. Primers were 
designed using Primer3 with a product size range of 75-200 bp (Table 3.1) and purchased 
in powdered form from Invitrogen. Primers were immediately suspended in TE buffer to a 
concentration of 100 µM/L, split into 15 µL aliquots and stored at -20˚C until use. Primers 
were validated through an 8-point temperature gradient to verify that each anneal at 60˚C 
and melt peaks were checked to ensure only one product was created. A 4-point primer 
concentration curve was also run using a 10 fold dilution (100, 10, 1, and 0.1 ng/µL) and 
tested in triplicate.  
 Five reference genes were tested: ribosomal protein l7 (rpl7), ribosomal protein l8 
(rpl8), eukaryotic elongation fact 1 alpha (eEF1A), TATA Box BiTATA Box Binding 
Protein Ending Protein (tbp), Beta-2-Microgobulin (B2m), and Beta-actin (ACTB; Table 
3.2). Reference gene primers were validated in the same manner as the experimental gene 
primers, and the reference gene with the best stabilization value was used. rpl7 was used 
for all gene expression work.  
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 Reactions were prepared using the iTaq Universal SYBR Green One-Step Kit (Bio-
Rad, Mississauga, Ontario) according to the manufacturer’s guidelines. Reactions were 
performed using RNA samples brought to a concentration of 40 ng/µL in TE buffer. A Bio-
Rad CFX96 was used for RT-qPCR analysis using the following settings: SYBR/FM; 
Reverse Transcription Reaction, 10 minutes at 50˚C; Polymerase Activation and DNA 
Denaturation, 1 minutes at 95˚C; Amplification: Denaturation at 95˚C, 10 seconds; 
Annealing/Extension + plate read at 60˚C, 10-30 seconds; Cycles, 45; Melt-Curve 
Analysis, 65-95˚C with 0.5˚C increments 2-5 seconds/step. Non-template controls were 
run for all primers to monitor contamination and primer-dimer formation. All samples were 
run in triplicate, and normalized to rpl7 transcript levels. Differences in gene expression 
between treatments were evaluated via statistical analysis using the 2-ΔΔCT (relative change 













β hydroxyacyl-CoA dehydrogenase (hcd) F:TTGCATGAGAGAGGTCACGG 
R:TGTGGGGATCCTTTGCACTC 
Schulz, 2008 XM_004065897.4 
HMG-CoA synthesis (hgs) F:TGACGTCACAGACAGGATGC 
R:CGCTTGGTCCACAAAATGGG 
Baenke et al., 2013 XM_011482022.2 
glucose-6-phosphate dehydrogenase (g6p) F:TGTTTTCTGCTTCGACAAGCG 
R:AGCCAGCAGAATACGATAGAGC 
Woo et al., 2011 XM_020704631.2 
stearoyl-CoA desaturase (scd) F:CCCAAACCTCGCAGGATGAT 
R:CCGTGATTCCCAGAGCACTT 
Baenke et al., 2013 XM_004080425 
acetyl-CoA carboxylase – 2 (ac2) F:ACGTGCAGTGGTTGTGTATGA 
R:ATCCGATCCCTGTCCTTCCA 
Baenke et al., 2013 XM_023958485.1 




Baenke et al., 2013 







Table 3.2. Primers used for reference genes in RT-qPCR analysis.  
Gene Name Primer Sequence NCBI Accession # 
ribosomal protein L7 (rpl7) F:CCCCAACTTGAAGTCTGTGC 
R:TGTTGGCAGGCTTGAAGTTC 
NM_001104870 
β-actin (actb) F:CCAGCCTTCCTTCCTTGGTA 
R:GTACCTCCAGACAGCACAGT 
S74868 
ribosomal protein L8 (rpl8) F:CCTGTTGAGCATCCATTCGG 
R:CCTTCTCCTGGACGGTCTTT 
NM_001104909 
elongation factor 1 alpha (eef1a) F:CAAGAACGACCCACCAAAGG 
R:CAATGGCAGCATCTCCAGAC 
NM_001104662 
TATA-box binding protein (tbp) F:GTGTTCAGTCCCATGATGCC 
R:AGTCTGTCCTGATGCTCCTG 
NM_001278855 






3.3.3 Statistical analysis 
 Metabolomics reports generated using the Agilent Fiehn Retention Time Locking 
Library were filtered using a R (v. 2.15.2) program designed at the University of North 
Texas (UNT, Denton, TX, USA) which determined acceptable metabolite identification 
based on the similarity between sample retention indices and library retention indices, and 
a net mass spectral quality score of 70% or greater as calculated by AMDIS. The 
metabolites with results that met all filtration criteria were included in a two-tailed Welch’s 
t-test, in order to determine statistically significant differences in RF values between the 
control and metformin and guanylurea treated groups.  The 2-ΔΔCT values from RT-qPCR 
analysis were analyzed using a single factor ANOVA, by treatment. An α of 0.05 was used 




3.4 Results  
3.4.1 Metabolite and gene expression analysis on larval medaka exposed to metformin 
 Larval medaka exposed to 3.2 µg · L-1 metformin from embryo through 28 days 
post hatch had significantly altered abundances of various metabolites (T-test, p < 0.05, 
Table 3.3). The fatty acids: stearic acid, palmitic acid, and arachidic acid, were all found 
to be significantly increased in metformin exposed larvae (T-test, p < 0.05), with RF values 
of 1.77, 1.54, and 2.59 respectively (Table 3.3). The amino acids L-lysine and L-proline 
were found to be significantly decreased in exposed larvae (T-test, p < 0.05) with RF values 
of 0.51 and 0.37, respectively (Table 3.3). The metabolite DL-3-aminoisobutyric acid was 
found to be significantly decreased (T-test, p < 0.05, RF = 0.60), while the metabolite 1-
methylnicotinamide was found to be significantly increased (T-test, p < 0.05, RF = 1.36) 
in exposed medaka larvae (Table 3.3). Lastly, the metabolite phosphoric acid was found to 
be significantly increased (T-test, p < 0.05) in metformin exposed larvae with a RF value 
of 2.13 (Table 3.3). RT-qPCR results (Table 3.4) revealed a significant down-regulation in 
the expression of hcd in metformin exposed larvae when compared to controls with a log2 
fold change of -1.60 (DF = 1, F = 31.6, p < 0.05). PCR analysis also showed a significant 
down-regulation in the expression of hgs with a fold change of -3.25 if exposed larvae (DF 
= 1, F = 17.9, p < 0.05). No significant difference, however, was seen in the expression any 




Table 3.3. Metabolites detected in larvae.  An * is used to denote significance between 







± 1 SD 
N 
Met 
Met Mean ± 
1 SD 
Met/Control 
(RF value) P-value 
*stearic acid 7 1340 ± 
301 
8 2380 ± 254 1.8 1.3E-05 
*palmitic acid 7 988± 115 8 1520 ± 203 1.5 5.0E-05 
*phosphoric acid 7 8890± 
4800 
8 18900 ±4340 2.1 1.1E-03 
*L-lysine 2 7 2420 ± 
677 
7 1240 ±275 0.5 2.8E-03 
*DL-3-
aminoisobutyric acid 2 
7 830 ± 
213 
8 500 ± 134 0.6 5.7E-03 
*arachidic acid 6 6.50 ± 
2.00 
8 16.9 ± 8.00 2.6 5.7E-03 





8 151 ±33.0 1.4 4.7E-02 
pyruvic acid 7 23.4 ± 
9.00 
6 14.0 ± 7.00 0.6 7.1E-02 
L-serine 2 7 4890 ± 
1290 
8 6490 ± 2180 1.3 1.1E-01 
putrescine 7 410± 
83.0 
8 328 ± 142 0.8 1.9E-01 
adenine 1 7 30.3 ± 
8.00 
8 35.6 ± 11.0 1.2 3.1E-01 
tyrosine 2 6 416± 125 8 339 ± 143 0.8 3.1E-01 
glycolic acid 7 35.4 ± 
19.0 
8 45.3 ± 20.0 1.3 3.4E-01 
D-malic acid 7 1110 ± 
313 
8 981 ± 228 0.9 3.7E-01 
L-pyroglutamic acid 5 2254 ± 
1280 
5 1620 ± 812 0.7 3.8E-01 
L-(+) lactic acid 7 11200± 
2450 
8 10100 ± 
2520 
0.9 4.1E-01 
urea 7 575± 187 8 663 ± 217 1.2 4.1E-01 
L-ornithine 2 7 274± 150 8 216 ± 133 0.8 4.4E-01 
Beta- alanine 1 7 296± 144 8 247 ± 86.0 0.8 4.5E-01 
L-mimosine 1 7 132 ± 
55.0 
8 113 ± 34.0 0.9 4.5E-01 
citraconic acid 1 6 17.8 ± 
10.0 
8 21.7 ± 9.00 1.2 4.7E-01 
DL-isoleucine 2 7 291± 133 8 340 ± 128 1.2 4.9E-01 
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picolonic acid 7 18.0 ± 
8.00 
7 16.7 ± 4.00 0.9 7.1E-01 
2-hydroxypyridine 7 345± 
91.0 
8 360 ± 67.0 1.0 7.4E-01 
oleic acid 7 125 ± 
67.0 
8 135 ± 58.0 1.1 7.5E-01 
L-valine 2 7 605± 136 8 631 ± 200 1.0 7.7E-01 
glycine 7 17800 ± 
3860 





7 555 ± 
126 
8 568 ± 68.0 1.0 8.1E-01 
hypoxanthine 1 7 1370± 
303 
8 1340 ± 183 1.0 8.3E-01 
4-guanidinobutyric 
acid 2 
7 1290 ± 
425 
8 1260 ± 370 1.0 8.6E-01 
fumaric acid 7 64.7 ± 
31.0 
8 65.3 ± 20.0 1.0 9.6E-01 
L-threonine 2 7 1630 ± 
357 
8 1630 ± 288 1.0 9.9E-01 
L-methionine 2 7 153 ± 
112 





Table 3.4 Gene expression results for 3.2 µg · L-1 metformin exposed larvae. An * is used 
to denote significant changes in gene expression between controls and medaka larvae 
exposed to metformin (α = 0.05). 2 larvae were homogenized per treatment replicate (n = 
3 for all groups).  
Gene name Log2 (fold Δ) p-value 
*β hydroxyacyl-CoA dehydrogenase (hcd) -1.60 5.0E-3 
*HMG-CoA synthesis (hgs) -3.25 0.02 
glucose-6-phosphate dehydrogenase (g6p) 0.41 0.11 
stearoyl-CoA desaturase (scd) -0.53 0.29 
acetyl-CoA carboxylase – 2 (ac2) -0.09 0.82 








Figure 3.1: Mean fold change (± 1 SE) in gene expression between metformin exposed and 
control larvae.  An asterisk * denotes significantly altered gene expression relative to 
controls (p < 0.05).  2 larvae were homogenized per treatment replicate (n = 3 for all 
groups).   
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3.4.2 Metabolite and gene expression analysis on larval medaka exposed to 
guanylurea 
 Similar to metformin exposed larvae, medaka exposed to 1.0 ng · L-1 guanylurea 
from embryo through 28 days post hatch had significantly altered abundances of various 
metabolites (T-test, p < 0.05, Table 3.5). All 7 altered metabolites in guanylurea treated 
fish were found to be significantly increased in abundance (T-test, p < 0.05, Table 3.5) 
when compared to control fish. Specifically, the metabolites  glucose-6-phosphate, 
panthothenic acid, putrescine, O-phosphocholamine, adenosine-5-monophosphate, and 
stearic acid were all shown to be increased when compared to control fish with RF values 
of  1.4, 1.6, 1.3, 1.1, 1,2, 1.8, and 1,8 respectively.  The results of the RT-qPCR analysis 
on guanylurea exposed medaka larvae (Table 3.6) revealed a significant down-regulation 
of ac2 in guanylurea exposed larvae when compared to controls with a log2 fold change of 
-0.88 (DF = 1, F = 10.25, p < 0.05). Additionally, a significant down-regulation in elo was 
seen in exposed larvae compared with controls with a fold change of -1.53 (DF = 1, F = 
9.84, p < 0.05). However, no significant differences were seen in the expression of the 




Table 3.5. Metabolites detected in larvae exposed to 1.0 ng · L-1 guanylurea.  An * is used 
to denote significance between control and guanylurea exposed larvae metabolite response 









Mean ± 1 SD 
Guan/Control 
(RF value) P-value 
*D-glucose-6-
phosphate 1 
8 865 ± 161 8 1200 ± 179 1.4 1.5E-03 
*pantothenic acid 2 8 227 ± 47.8 8 305 ± 55.3 1.3 9.1E-03 
*putrescine 8 274 ± 31.8 8 307 ± 22.0 1.1 3.1E-02 
*O-phosphocolamine 8 968 ± 139 8 1160 ± 192 1.2 4.3E-02 
*adenosine-5-
monophosphate 1 
8 192 ± 125 8 347 ± 158 1.8 4.8E-02 
*stearic acid 8 1120 ± 176 8 1990 ± 1030 1.8 4.8E-02 
2,3-
dihydroxypyridine 
8 25.4 ± 18.5 8 11.1 ± 3.80 0.4 6.8E-02 
palmitic acid 8 754 ± 109 8 1170 ± 546 1.6 6.8E-02 
5-aminovaleric acid 1 8 41.1 ± 15.6 8 28.2 ± 11.3 0.7 8.0E-02 
guanosine 1 8 145 ± 42.0 8 192 ± 59.3 1.3 8.7E-02 
L-methionine 2 8 374 ± 162 5 257 ± 40.5 0.7 8.8E-02 
L-histidine 3 8 2690± 655 8 3200 ± 414 1.2 8.8E-02 
uric acid 1 6 4060 ± 751 8 5180 ± 1500 1.3 9.4E-02 
tyrosine 2 8 779 ± 267 8 581 ± 159 0.7 9.7E-02 
N-methyl-DL-
glutamic acid 3  
8 66.2 ± 9.30 6 75.5 ± 9.70 1.1 1.0E-01 
hypotaurine 7 101 ± 57.6 7 58.8 ± 11.4 0.6 1.0E-01 
N-acetyl-L-aspartic 
acid 1 
8 602 ± 69.1 8 702 ± 149 1.2 1.2E-01 
glycerol 1-phosphate 8 2650 ± 362 8 3050 ± 591 1.2 1.3E-01 
D-malic acid 8 1340 ± 193 8 1190 ± 176 0.9 1.4E-01 
dihydroxyacetone 
phosphate 2 
8 154 ± 22.4 8 185 ± 50.6 1.2 1.4E-01 
methyl-beta-D-
galactopyranoside 
7 250 ± 147 8 155 ± 72.4 0.6 1.6E-01 
L-valine 2 8 717 ± 369 8 514 ± 122 0.7 1.8E-01 
iminodiacetic acid 2 7 118 ± 49.7 7 219  ± 174 1.9 1.8E-01 
glycine 8 8390 ± 1710 8 10000 ± 
2840 
1.2 1.9E-01 
L-ornithine 2 7 571 ± 212 8 449.0 ± 128 0.8 2.2E-01 
urea 8 770 ± 231 5 467 ± 467 0.6 2.3E-01 
N-acetyl-D-
mannosamine 1 
8 80.4 ± 21.3 8 104 ± 48.8 1.3 2.4E-01 
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allo-inositol 8 2650 ± 416 8 3390 ± 1600 1.3 2.4E-01 
L-proline 2 8 566 ± 509 7 331 ± 102 0.6 2.4E-01 
aspartic acid 2 8 1660 ± 328 7 2040 ± 733 1.2 2.4E-01 
beta-
glycerolphosphate 
8 19.7 ± 4.40 8 22.8 ± 5.70 1.2 2.4E-01 
arachidic acid 7 9.30 ± 5.60 7 13.1 ± 7.20 1.4 3.0E-01 
hypoxanthine 1 8 2210 ± 578 8 1930 ± 442 0.9 3.0E-01 
3-phosphoglyceric 
acid 
7 387 ± 29.5 8 424 ± 89.5 1.1 3.0E-01 
D-lyxose 2 8 5670 ± 1430 8 5060 ± 699 0.9 3.0E-01 
isomaltose 1 8 82.9 ± 52.9 8 61.7 ± 18.0 0.7 3.1E-01 
4-aminobenzoic acid 5 29.6 ± 4.20 7 33.6 ± 8.60 1.1 3.2E-01 
N-acetyl-L-histidine 
2 
8 1390 ± 634 8 1670 ± 410 1.2 3.3E-01 
uridine 5'-
monophosphate 2 
7 90.3 ± 57.7 8 125 ± 77.9 1.4 3.4E-01 
pyruvic acid 8 57.5 ± 14.7 7 63.0 ± 6.30 1.1 3.6E-01 
inosine 8 3960 ± 811 8 3580 ± 801 0.9 3.6E-01 
N-methylalanine 6 98.8 ± 37.2 8 79.7 ± 38.6 0.8 3.7E-01 
tagatose 2 5 76.2 ± 8.20 5 101 ± 53.3 1.3 3.7E-01 
trans-4-hydroxy-L-
proline 2 
8 1100 ± 585 8 854 ± 501 0.8 3.8E-01 
D-allose 1 8 3300 ± 693 7 3580 ± 508 1.1 3.9E-01 
cholesterol 8 1130 ± 366 8 1350 ± 585 1.2 3.9E-01 
picolonic acid 8 14.7 ± 4.50 8 17.2 ± 6.04 1.2 3.9E-01 
L-tryptophan 2 6 128 ± 76.5 6 98.7 ± 19.4 0.8 4.0E-01 
2-hydroxypyridine 8 145 ± 18.1 7 155 ± 28.2 1.1 4.1E-01 
dehydroascorbic 
acid  4 
8 76.2 ± 21.8 6 91.8 ± 40.0 1.2 4.2E-01 
xylitol 8 23.7 ± 5.20 8 26.3 ± 7.50 1.1 4.4E-01 
1-methyl 
nicotinamide 1 
8 97.7 ± 33.3 8 114 ± 48.4 1.2 4.4E-01 
L-threonine 2 8 1790 ± 713 8 1570 ± 374 0.9 4.7E-01 
L-cysteine 2 8 155 ± 69.7 8 134 ± 35.1 0.9 4.7E-01 
adenine 1 8 27.8 ± 7.50 8 30.2 ± 5.50 1.1 4.8E-01 
urea 8 770 ± 231 8 643 ± 431 0.8 4.8E-01 
D-ribose-5-phosphate 
1 
8 161 ± 65.9 8 226 ± 248 1.4 4.9E-01 
DL-glyceraldehyde 
3-phosphate 2 
7 24.7 ± 3.80 8 26.8 ± 7.30 1.1 5.0E-01 
cellobiose 2 7 178  ± 156 5 125 ± 104 0.7 5.0E-01 
dioctyl phthalate 5 5.30 ± 7.00 7 3.00 ± 2.50 0.6 5.1E-01 
ribulose-5-phosphate 
3 
7 253 ± 84.6 7 280 ± 59.6 1.1 5.1E-01 
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L-glutamine 2 8 1360 ± 699 6 1190 ± 229 0.9 5.4E-01 
phosphoric acid 8 10600 ± 4000 8 11800 ± 
4220 
1.1 5.7E-01 
L-serine 2 8 4650 ± 1720 6 4950 ± 245 1.1 6.4E-01 
porphine 1 6 6.50 ± 2.70 6 7.30 ± 3.40 1.1 6.4E-01 
4-guanidinobutyric 
acid 2 
8 1360 ± 567 8 1250 ± 328 0.9 6.5E-01 
glyceric acid 8 24.6 ± 9.40 6 22.8 ± 5.50 0.9 6.7E-01 
oleic acid 7 179 ± 63.2 8 164 ± 75.7 0.9 6.8E-01 
Creatinine 8 2900 ± 596 8 2730 ± 1110 0.9 7.1E-01 
L-asparagine 2 7 956 ± 459 8 846 ± 820 0.9 7.5E-01 
xanthine 8 248 ± 84.5 8 259 ± 37.3 1.0 7.6E-01 
maltose  2 5 1640 ± 713 6 1540 ± 394 0.9 7.7E-01 
isopropyl beta-D-1-
thiogalactopyranoside 
8 81.8 ± 27.6 6 77.7 ± 31.2 0.9 8.0E-01 
6-phosphogluconic 
acid 
7 107 ± 36.5 7 112 ± 39.6 1.0 8.1E-01 
fumaric acid 8 147 ± 32.0 8 142. ± 42.6 1.0 8.2E-01 
D-glucose 1 8 9130 ± 4420 8 8730 ± 2080 1.0 8.2E-01 




8 766 ± 187 8 750 ± 156 1.0 8.6E-01 
Beta- alanine  1 8 250 ± 24.4 8 248 ± 25.7 1.0 8.8E-01 
glycolic acid 7 33.5 ± 29.8 7 35.3 ± 11.7 1.1 8.8E-01 
L-mimosine 1 8 73.3 ± 16.9 8 73.4 ± 25.9 1.0 9.9E-01 





Table 3.6 Gene expression results for larvae exposed to ng · L-1 guanylurea. An * is used 
to denote significant changes in gene expression between controls and medaka larvae 
exposed to guanylurea (α = 0.05). 2 larvae were homogenized per treatment replicate (n = 
3 for all groups).  
Gene name Log2 (fold Δ) p-value 
*acetyl-CoA carboxylase – 2 (ac2) -0.88 0.03 
*elongation of very long chain fatty acids protein 
1-like (elo) 
-1.53 0.04 
β hydroxyacyl-CoA dehydrogenase (hcd) -0.27 0.25 
stearoyl-CoA desaturase (scd) -0.35 0.43 
HMG-CoA synthesis (hgs) 0.78 0.52 






Figure 3.2: Mean fold change (± 1 SE) in gene expression between guanylurea exposed 
and control larvae.  An asterisk * denotes significantly altered gene expression relative to 






 Changes in metabolite response factors and gene expression offer information 
about cellular pathways potentially affected by the presence of aquatic contaminants, such 
as metformin and its metabolite guanylurea. The diminished size of larval medaka seen in 
Chapter 2 may be attributed to disruptions in cellular pathways, indicated by the significant 
alterations seen in specific metabolites, as shown in the present chapter. 
 One such metabolite, L-lysine, is an essential amino acid and is part of the 
intermediatory metabolism in the tricarboxylic acid (TCA) cycle (Kokushi et al., 2012). L-
lysine is metabolized to produce acetyl-CoA (Khan et al., 2016), which is a necessary 
molecule entering the TCA cycle, as it is oxidized by the mitochondria for energy for the 
cell (Reece and Niel, 2011). The decrease seen in L-lysine in metformin exposed fish could 
be due to this amino acid being converted to ketone bodies. Ketone bodies are typically 
produced from fatty acids, however the production of ketone bodies by L-lysine has been 
shown to occur under instances where metabolic conditions may be disrupted (Fasulo et 
al., 2012) such as what is potentially happening with our metformin exposed larvae, as we 
see fatty acid dysregulation. Similar to other amino acids, L-lysine plays an important role 
in building muscle proteins (Xu et al., 2012), thus the deficiency in L-lysine seen in 
metformin exposed fish could explain the stunted growth reported in Chapter 2. HMG-
CoA synthase (hgs) catalyzes the formation of HMG-CoA from acetoacetyl-CoA and 
acetyl-CoA in the sterol biosynthetic pathway (Ercal and Crawford, 2017). Recent studies 
have demonstrated that hgs is regulated by lysine acetylation and succinylation, which 
increases hgs activity (Ercal and Crawford, 2017). A significant down-regulation in hgs 
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expression was seen in metformin exposed larvae when compared to controls, likely caused 
by the decrease in L-lysine present in the exposed fish. HMG-CoA synthase is important 
for regulating the flux through the isoprenoid/mevalonate pathway and therefore important 
in controlling cell growth and the synthesis of cholesterol (Harris et al., 2000), thus altered 
expression of hgs can lead to a dysregulation of such endpoints.  
 Another explanation for the stunted growth seen in metformin exposed larvae is the 
significant decrease in the amino acid, L-proline. Arginine is taken up by cells and 
metabolized into L-proline, which is then used as a precursor to collagen formation (Endo 
et al., 2003). One of the proposed mechanisms of actions (MOA) of metformin in patients 
with type-2 diabetes is through the activation of adenosine monophosphate kinase 
(AMPK), which inhibits the target rapamycin (mTOR) signaling pathway that regulates 
energy utilization, thus down-regulating gluconeogenesis in the liver (Crago et al., 2016; 
Goodyear et al., 2001; Kahn et al., 2005; Viollet et al., 2012). The inhibition of mTOR in 
combination with nutrient stress (such as the dysregulation in lipids and fatty acids as seen 
in metformin exposed larvae), however, also leads to the induction of proline oxidase 
(POX) activity (Pandhare et al., 2009), resulting in the metabolism of proline. Proline 
metabolism is important during times of nutrient stress, as proline is readily available from 
the breakdown of the extracellular matrix (ECM) with its degradation resulting in the 
generation of adenosine triphosphate (ATP; Pengfei et al., 2011). The ECM is composed 
predominantly of collagen, with the major contributor to the production of collagen being 
proline (Pandhare et al., 2009). The ECM is a highly dynamic structure, and its remodeling 
is an effective mechanism whereby diverse cellular behaviors such as cell proliferation, 
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adhesion and migration, cell differentiation, and cell death can be regulated (Pengfei et al., 
2011). However, prolonged degradation of the ECM is concerning, as it can lead to 
abnormal ECM dynamics such as deregulated cell proliferation and invasion, failure of cell 
death, and loss of cell differentiation (Pandhare et al., 2009). This decrease in L-proline is 
corroborated by the increase seen in phosphoric acid in metformin exposed larvae when 
compared to control fish, as phosphoric acid is a direct by product of the degradation of 
proline (Abdullah et al., 2017). 
 A common mechanism of action that has been proposed for metformin is through 
AMPK, as AMPK has also been defined as the upstream kinase for the critical metabolic 
enzymes acetyl-CoA carboxylase (ACC) and HMG-CoA reductase (HGR), which function 
in the rate limiting steps for fatty acid and sterol synthesis (Bjorklund et al., 2010; Zagorska 
et al., 2010; Zhang et al., 1999). In this sense, the activation of AMPK phosphorylates 
ACC, causing it to be deactivated. When acetyl-CoA carboxylase is active, melanyl-CoA 
is produced, which is the building block for new fatty acids (Mihaylova and Shaw, 2011). 
With the proposed activation of AMPK by metformin, AMPK will acutely control lipid 
metabolism through phosphorylation of ACC (Li et al., 2011) leading to a decrease in the 
synthesis of fatty acids (Mihaylova and Shaw, 2011). In order to rule this mechanism of 
action out, we sought to investigate the expression of acetyl-CoA carboxylase-2 (ac2) in 
metformin and guanylurea treated larvae. No difference in the expression of ac2 was seen 
between the treatments for metformin, however a significant down-regulation was seen in 
guanylurea exposed larvae when compared to controls, which could explain the stunted 
growth seen in guanylurea exposed larvae.  
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 The increase seen in important fatty acids such as stearic and palmitic acid may 
also help explain the stunted growth seen in metformin and guanylurea exposed fish. 
Palmitic acid is the most common saturated fatty acid which is elongated to stearic acid 
(Malgorzata et al., 2017). Stearic acid is a saturated fatty acid that is metabolized to oleic 
acid via steroyl-CoA desaturase (scd), and the ratio of stearic acid to oleic acid has been 
implicated in the regulation of cell growth and differentiation (Zhang et al., 1999). 
Although the levels of oleic acid were not high enough to be considered significantly 
different between the metformin and guanylurea exposed larvae and their respective 
controls, we sought to rule out this decrease in the stearic acid conversion by investigating 
the expression of scd as the possible mechanism by which stearic acid RFs increased. The 
RT-qPCR results, however revealed no significant changes in the expression of scd 
between treatments (Tables 3.4 and 3.6). Additionally, elongation of very long chain fatty 
acid protein like-1 (elo) can be found numerous times throughout the fatty acid synthase 
pathway. The protein elo functions as an elongase catalyzing the synthesis of both saturated 
very long-chain fatty acids (VLCFA) and mono-unsaturated VLCFA (Ofman et al., 2010). 
Additionally, elo knockdown in humans has been shown to reduce the elongation of C22:0 
and C26:0 fatty acids (Ofman et al., 2010). With this in mind, we sought to investigate if 
elo expression is altered in metformin and guanylurea exposed fish, which could explain 
the accumulation of fatty acids, such as palmitic and stearic, seen in exposed larvae. 
Interestingly, RT-qPCR results revealed no significant changes in the expression of elo 
between metformin exposed and control larvae. However, results show a significant 
decrease in the expression of elo in guanylurea exposed fish. Maintaining proper ratios of 
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fatty acids is important for cell growth and differentiation, as they participate in cell 
membrane fluidity and cell signaling (Zhang et al., 1999).  
 The β-oxidation pathway is an important pathway in which fatty acids are broken 
down to produce energy (Lopaschuk et al., 2010). Specifically, β-oxidation produces 
acetyl-CoA, nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide 
(FADH2), where the acetyl-CoA produced enters the TCA cycle and the NADH and 
FADH2 produced are used in the electron transport chain to produce ATP (Schulz, 2008). 
The NADH produced during β-oxidation is catalyzed by β hydroxyacyl-CoA 
dehydrogenase (hcd), and is thus an important rate limiting step in energy production 
(Schulz, 2008). Interestingly, no significant difference was seen in the expression of hcd 
in guanylurea treated fish, while a significant decrease was seen in the expression of hcd 
in metformin exposed fish when compared to controls, potentially leading to a decrease in 
β-oxidation output. This could be the reason we are seeing an increase in the metabolism 
of L-lysine in metformin exposed fish, as the cell is desperate for acetyl-CoA to enter the 
TCA cycle.  
 Pantothenic acid is a component of coenzyme A (CoA) molecule along with 
adenosine-5-monophosphate (AMP) and cysteine, and is a necessary nutrient that must be 
obtained through dietary sources (Leonardi and Jackowski, 2007). Pantothenic acid and 
AMP, in their functions as cofactors for CoA, are necessary for the synthesis of many 
compounds including fatty acids, cholesterol, steroid hormones, neurotransmitters, amino 
acids, and are necessary for energy extraction during the β-oxidation of fatty acids and the 
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oxidation of amino acids (Leonardi and Jackowski, 2007). Pantothenic acid and CoA play 
a central role in the acylation of proteins with fatty acids, mainly myristic and palmitic 
acids (Leonardi and Jackowski, 2007). Both pantothenic acid and AMP were found to be 
significantly increased in guanylurea exposed larvae when compared to controls, 
potentially in an attempt to increase the biosynthesis of fatty acids.  
 The pentose phosphate pathway is an important metabolic pathway supplying 
energy to cells by maintaining the level of the co-enzyme nicotinamide adenine 
dinucleotide phosphate (NADPH) which is important for tissues involved in the 
biosynthesis of fatty acids or isoprenoids (Thomas et al., 1991). An important enzyme in 
this pathway is glucose-6-phosphate dehydrogenase (g6p) which reduces NADP+ to 
NADPH while oxidizing glucose 6-phosphate (Aster et al., 2010). Because of the 
significant increase in glucose-6-phosphate in guanylurea exposed fish, we sought to 
investigate whether g6p expression was altered, which could assist in the explanation of 
the increased metabolite. However, no significant difference in the expression of g6p was 
seen between the treatments, thus another explanation for the increased glucose-6-
phosphate should be investigated.  
 The abundance of palmitic acid seen in metformin exposed fish may also explain 
the increased amount of arachidic acid found in exposed larvae when compared to controls, 
as palmitic acid is first converted to stearic acid via elongase, which is then converted to 
oleic acid via steroyl-CoA desaturase, then converted to linoleic acid via Δ12-desaturase 
(Akoh and Min, 2002).  Linoleic acid is then converted to gamma-linolenic acid in the 
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reaction catalyzed by Δ6-desaturase, then it is elongated to form dihomo-gamma-linolenic 
acid, which in turn is desaturated in the reaction catalyzed by Δ5-desaturase to form 
arachidonic acid (Akoh and Min, 2002). Arachidonic acid is the precursor of many 
eicosanoids such as prostaglandins, thromboxanes, and leukotrienes, however it can also 
be hydrogenated to arachidic acid (Akoh and Min, 2002). Thus, the increased levels of 
arachidic acid seen in metformin exposed fish might be due to a rapid increase in plasma 
arachidonic acid levels (Valeem, 2012). The hydrogenation of arachidonic acid inhibits the 
production of arachidonic acid related eicosanoids such as prostaglandins, thromboxanes, 
and leukotrienes (Akoh and Min, 2002; Ruan et al., 2010; Yui et al., 2016) potentially 
leading to the growth retardation seen in metformin and guanylurea exposed larvae.  
 Putrescine is the simplest of the polyamines, serving as a precursor to all higher 
PAs and is found in all eukaryotes (Bridges et al., 2018). An early response to central 
nervous system (CNS) injury is the induction of PA metabolism, resulting in increased 
levels of putrescine (Adibhatla et al., 2002; Muller et al., 2007), which we see in 
guanylurea exposed larvae. O-phosphocolamine was also found to be significantly 
increased in guanylurea exposed larvae when compared to controls. O-phosphocolamine 
is an ethanolamine derivative that is used to construct the phospholipids, 
glycerophospholipid and sphingomyelin (Toda et al., 2017). Sphingomyelin is an 
important sphingolipid which are of great importance in the nervous system, playing a role 
in cell signaling cascades which mediate cellular apoptosis, proliferation, stress response, 
necrosis, and differentiation (Bridges et al., 2018; Perry and Hannun, 1998). The increase 
in both putrescine and O-phosphocolamine is indicative of potential CNS damage, however 
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a more targeted investigative approach such as whole brain metabolomics could better 
investigate the potential neurotoxic behavior of guanylurea. Interestingly, and what should 
be of great concern is that FHM larvae exposed via maternal transfer to MeHg, a compound 
known to cause CNS damage, showed a similar metabolic profile with the elevation of 
putrescine and O-phosphocolamine (Bridges et al., 2018).  
 The significant increase in methyl-nicatinamide (MNA) seen in metformin exposed 
larvae can also be attributed to the reduction in size of the metformin exposed medaka seen 
in Chapter 2. An increase in MNA indicates peroxisome proliferation related to 
inflammation, obesity, and metabolic syndrome, and has been shown to be a byproduct 
which is formed during the conversion of S-adenosylmethionine (SAMe) to S-
adenosylhomocysteine (SAH) (Tyagi et al., 2014). The SAH produced is utilized in the 
trans-sulfuration pathway to regenerate glutathione (GSH; Tyagi et al., 2014). It has been 
suggested that the increase in MNA found in organisms might be due to the upregulation 
of enzymes involved in the regeneration of GSH via SAH and other intermediates which 
results in increased produced of GSH and its utilization due to more production of reactive 
oxygen species (ROS) to cope with potential oxidative stress (Tyagi et al., 2014). 
 β-aminoisobutyric acid (BAIBA) is a small molecule metabolite, which has been 
recently identified as potential novel myokine and has been inversely associated with 
cardiometabolic risk including fasting glucose and insulin (Roberts et al., 2014). BAIBA 
induces white fat browning, with its plasma level increasing with exercise, whereas the low 
plasma concentration is associated with the metabolic risk factors such as high cholesterol, 
triacylglycerol and body mass index (Roberts et al., 2014). The decrease in BAIBA seen 
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in metformin exposed larvae could be a result of the lack of movement of the exposed fish 
due to the lipid/amino acid dysregulation potentially leading to a disruption of energy 
stores, and thus a lack a movement in the energy deprived fish.  
 Overall, these findings demonstrate the need for even further research into the 
biochemical effects of metformin and its metabolite guanylurea on non-target aquatic 
organisms, such as fish. It is apparent from the research presented thus far that the 
environmentally relevant concentrations of both compounds is able to cause detectable 
changes in the metabolome of exposed Japanese medaka, as well as changes in expression 
of associated genes. From this research, it is reasonable to conclude that current 
concentrations of both compounds in surface waters may lead to adverse consequences for 












Chapter 4: Effects of metformin and 
guanylurea on the full life-cycle of 






 While fish ELS studies generate a multitude of valuable data, they are not reliable 
in determining how emerging/novel compounds affect the full life-cycle of fish. Such 
studies help to determine how compounds, such as metformin and guanylurea, affect 
aquatic organisms over all developmental and reproductive stages. Japanese medaka 
(Oryzias latipes) were chronically exposed to environmentally relevant concentrations of 
metformin and guanylurea alone and in mixture from embryo through sexual maturity (165 
days). The growth, steroid hormone and vitellogenin production, and reproductive output 
were examined. While metformin and guanylurea treatment alone, and in combination, did 
not significantly stunt the growth of medaka, exposure to the compounds did significantly 
alter the production of important sex steroid hormones in both male and female medaka. 
However, exposure to metformin and guanylurea alone, or in mixture, did not affect the 
production of the egg yolk precursor protein, vitellogenin, in male medaka. Interestingly, 
no significant effects on reproductive output were seen in the present study. To our 
knowledge, this research is the first to study the exposure effects of environmentally 
relevant concentrations of metformin and guanylurea alone and in combination over the 





 Chapter 2 demonstrated that exposure to low concentrations of metformin and 
guanylurea caused growth retardation in larval Japanese medaka (Oryzias latipes), while 
Chapter 3 outlined the potential mechanisms of action with which metformin and 
guanylurea elicits the aforementioned growth effects. Development, especially early 
development, is a sensitive period in the life-cycle of an organism, which includes (but is 
not limited to) important pathways for sexual differentiation (Johns et al., 2011). While it 
is too early to show sexual differentiation and reproductive effects in 28 day old medaka, 
the dysregulation of arachidic acid seen in metformin treated fish (3.4.1 Metabolite and 
gene expression analysis on larval medaka exposed to metformin) indicates that the 
hormonal processes of adult medaka could potentially be effected.  
 In short, the therapeutic path of metformin in patients with type-2 diabetes and 
PCOS is to act on metabolic pathways to promote catabolism and glucose uptake, causing 
a sensitization of cells to insulin, thereby affecting pathways which are regulated by insulin, 
such as steroidogenic pathways (Niemuth et al., 2015). Metformin has been shown to affect 
the expression of cytochrome p450 11A and 3β-hydroxysteroid dehydrogenase and the 
cholesterol transporter steroid acute regulatory protein, all steroidogenic enzymes, in 
mammals at concentrations ranging from 10 mg/kg/d to 250 mg/kg/d (Viollet et al., 2012). 
Metformin exposure (40 µg · L-1) caused a more than 30-fold overexpression of the egg 
yolk precursor, vitellogenin (VTG) mRNA, with a significant induction of tests-ova in 
male FHM (Niemuth et al., 2015; Niemuth and Klaper, 2016). Additionally, FHM mating 
pairs exposed to metformin from 30 days post hatch until adulthood, produced significantly 
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fewer egg clutches over time when compared to control mating pairs (Niemuth et al., 
2015). At this time, no experiment found in the literature has investigated the effects of 
both metformin and guanylurea on the full life-cycle of fish, being sure to capture the 
sensitive early life-stage from embryo to 28 days. To the best of our knowledge, the only 
experiment in the literature started experimental treatments at 30 days post hatch (Niemuth 
and Klaper, 2016). Additionally, the effects of guanylurea exposure from any window of 
development through adulthood have yet to be determined. Furthermore, reports on the 
effects of metformin and its metabolite guanylurea on the gonadosomatic index (GSI) and 
hepatosomatic index (HIS) index of exposed fish have not been shown. GSI and HSI are 
common analyses that can offer the information on the general health of aquatic organisms. 
Altered GSI and HSI are common endpoints that can offer the information on the general 
health of aquatic organisms (Environmental Protection Department of Hong Kong, 2005).  
 The work presented thus far in the dissertation, combined with the limited research 
found in the literature, demonstrate the need to investigate the effects of both metformin 
and its metabolite guanylurea on the full life cycle of fish. Full life-cycle experiments are 
important to aid in assessing both lethal and sublethal responses to aquatic contaminants, 
as they follow fish from the egg stage through all stages of development (Parrott and 
Metcalfe, 2017). This chapter aimed to address a number of gaps in the literature by 
investigating the exposure effects of metformin and guanylurea on the full life cycle 
(embryo through sexual maturity), with specific aims targeted at growth, steroid hormone 





 The objectives of this experiment were to: 
 Assess the growth effects (length, wet weight, and condition factor) of metformin 
and guanylurea alone, and in combination, on the full life-cycle of Japanese 
medaka.  
 Assess the gonadosomatic and hepatosomatic index effects of metformin and 
guanylurea alone, and in combinations, on the full life-cycle of Japanese medaka. 
 Determine if Japanese medaka exposed to metformin and guanylurea alone, and in 
combination, cause altered production of the steroid hormones: estradiol and 11-
keto Testosterone. 
 Determine if male Japanese medaka exposed to metformin and guanylurea alone, 
and in combination, cause altered concentration of the protein: vitellogenin.  
 Assess the reproductive (daily egg output) effects of Japanese medaka exposed to 





 Ho1: Exposure of adult medaka to metformin and guanylurea alone, and in 
combination, will not cause a significant difference in the growth (length, wet weight, and 
condition factor) when compared to control fish.  
 Ho2: Exposure of adult medaka to metformin and guanylurea alone, and in 
combination, will not cause a significant effect in the gonadosomatic and hepatosomatic 
index when compared to control fish. 
 Ho3: Steroid hormone production in adult medaka exposed to metformin and 
guanylurea alone, and in combination, will not be significantly altered when compared to 
control fish.  
 Ho4: Vitellogenin concentration in adult male medaka exposed to metformin and 
guanylurea alone, and in combination, will not be significantly different when compared 
to control fish.  
 Ho5: Exposure to metformin and guanylurea alone, and in combination, will not 





4.3 Materials and methods 
4.3.1 Chemicals and analysis kits 
 Metformin hydrochloride (1,1-dimethylbiguanideine hydrochloride; CAS# 1115-
70-4) was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada). 
Guanylurea (CAS# 141-83-3) was purchased from Sigma-Aldrich (Oakville, Ontario, 
Canada) and methanol (CAS# 67-56-1) from ACP Chemicals Inc. (Montreal, Quebec, 
Canada). Formic acid (CAS# F0507) and sulfuric acid (CAS# 339741) was purchased from 
Sigma Aldrich (St. Louis, Missouri, United States). Cayman Chemical Estradiol (item # 
58221) and 11-keto Testosterone (item # 582751) ELISA kits were purchased from 
Cayman Chemical (Ann Arbor, Michigan, United States). Medaka vitellogenin ELISA kit 
(product # V01013403), produced by Biosence Laboratories, and was also purchased from 
Cayman Chemical.  
4.3.2 Animal care 
 The culturing and housing of Japanese medaka was performed in the same manner 
as described in 2.3.2 Animal care.  
4.3.3 Metformin and guanylurea exposure assays 
 Medaka embryos were collected as previously described in 2.3.2 Animal care. 
Embryos were once again separated by sex 118 h post-fertilization and were then kept 
separate until fish were arranged into respective exposure breeding harems. Viable 
embryos were randomly assigned to a waterborne treatment containing either 1.0 ng · L-1 
guanylurea, 7.5 µg · L-1 guanylurea, 3.2 µg · L-1 metformin, a mixture (3.2 µg · L-1 
metformin + 7.5 µg · L-1 guanylurea), or a control treatment. Embryos were maintained in 
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plastic petri dishes (Fisher Scientific, 60x15 mm), each containing 20-mL of the treatment 
solution. Four replicates per treatment (per sex) were used, with each replicate containing 
30 embryos. Exposure solutions were renewed daily, and were prepared using a 100,000 
µg · L-1 metformin or guanylurea master stock. The master stock did not exceed metformin 
or guanylurea’s solubility limits in water, and therefore no solvent was needed for the life-
cycle studies.  
All embryos were exposed to their assigned treatment solutions in a temperature 
controlled room (27 ˚C) and a 16:8 (light: dark) photoperiod with 0.5 hours each of dawn 
and dusk included in the light phase. Embryos were monitored under a dissecting 
stereomicroscope LEICA EZ4D (20x magnification) daily, using the developmental 
staging methods described by Iwamatsu (2004) and Wakamatsu (2003). Occurrence of 
developmental abnormalities, mortality, hatch success, and time-to-hatch were recorded 
daily.  
Upon hatch, larval medaka were transferred to 1-L plastic trays corresponding to 
their exposure concentration and replicate number for 30 days before being transferred to 
10-L tanks each containing 10 fish in breeding ratios of two males to three females, still in 
replicates of four. Extra fish were euthanized in water containing tricaine methane-
sulphonate (200 mg · L-1), buffered with sodium bicarbonate (400 mg · L-1) and flash frozen 
in liquid nitrogen. Fish were to be left in breeding replicates until age of successful 
breeding, however medaka males in control tanks began exhibiting aggressive behavior, 
some wounding each other to the point of mortality. Interestingly, metformin and 
guanylurea exposed fish were not exhibiting as much aggressive behavior, which could be 
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a ‘side-effect’ of compound exposure. At this point, the four replicates were mixed and 
divided into three large replicates and housed in 70-L tanks filled to a volume of 45-L. 
Medaka were housed in the 70-L tanks  in their treatments (3 replicates/treatment) for the 
remainder of the study. Target waterborne concentrations of metformin (3.2 µg · L-1), 
guanylurea (1.0 ng · L-1 and 7.5 µg · L-1), and the mixture treatment (3.2 µg · L-1 metformin 
+ 7.5 µg · L-1 guanylurea) were achieved using a Watson-Marlow 200 Series 16-channel 
peristaltic pump, which delivered stock concentrations from 1-L brown bottles in the 
appropriate volumes. Stocks of both metformin and guanylurea were prepared in clean 
water from a 100,000 µg· L-1 master stock prepared in DI water. Exposure solution volume 
exchange insured ~95% molecular turnover in 24 hours in each exposure tank. Fish were 
fed 15 mL of Premium Grade Brine Shrimp (Brine Shrimp Direct, San Francisco, 
California) twice per day for the first 28-days of the exposure, with the volume of brine 
increasing by 5 mL every other week until total brine volume reached 80 mL, which was 
held constant for the reminder of the exposure. 
4.3.4 Biological endpoints 
 Once egg production in each control tank reached steady state (roughly 10 
eggs/reproductive female/day) eggs were collected and counted for a total of 10 days. Eggs 
were collected from each replicate tank by gently stripping eggs from each gravid female 
with a gloved finger and placed into 50 mL of corresponding treatment solution and 
transported to the temperature control room to be counted. Debris was removed from 
embryos by gently rolling them on a clean paper towel. Embryos from each replicate were 
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kept in separate in their corresponding exposure solutions. Eggs from each treatment 
replicate were counted for 10 consecutive days.    
 At the close of the study (165 days), the remaining fish from the study were 
collected and euthanized in water containing tricaine methane-sulphonate (200 mg · L-1), 
buffered with sodium bicarbonate (400 mg · L-1). Individual fish length was measured 
using a digital caliper, and wet weight was measured using a Metler Toledo balance 
(AB204-S). Fish were dissected for liver and gonads. Each male and female liver was 
weight using a Metler Toledo balance (AB204-S), flash frozen and stored for steroid 
hormone and VTG (male only) analysis. Additionally, female gonads were weighed, flash 
frozen, and stored for future analyses. Condition factor was calculated via the following 
medaka established equation, weight (g) x 105/length (mm)3 (Foran et al., 2003). 
Hepatosomatic index was calculated using the equation, liver weight (mg)/total body wet 
weight (mg). Gonadosomatic index was calculated using the equation, gonad weight 
(mg)/total body wet weight (mg).   
4.3.5 Steroid analysis 
4.3.5a Steroid extraction 
 One liver was used for per sample for female steroid analysis, while 2 livers were 
pooled per male sample (n = 3) per treatment. Livers were homogenized using a hand held 
homogenizer in 400 µL of phosphate buffered saline (PBS) in a 1.5 mL microcentrifuge 
tube. Once homogenized, samples were centrifuged at 10,000 g for 10 minutes. After 
centrifugation, the supernatant was collected into a new 1.5 mL tube. 600 µL of methanol 
was added to the supernatant, then samples were centrifuged at 5000 g for 5 minutes. The 
102 
 
supernatant was transferred to a fresh 2 mL microcentrifuge tube, 1 mL of DI water with 
1% formic acid was added, then samples were vortexed.  
 Solid phase extraction (SPE, Oasis® HLB 3cc (60 mg)) cartridges arranged on a 
vacuum manifold were conditioned using 2 mL of methanol (this methanol is discarded as 
waste), followed by an equilibration step with 2 mL of DI water with 0.1% formic acid, 
again discarded as waste. Samples were then loaded into the SPE cartridges, followed by 
a second wash with 2 mL of DI water with 0.1% formic acid, then a final was with 2 mL 
of 1:1 methanol:DI water with 0.1% formic acid; discarded as waste. Clean and labeled 1.5 
mL microcentrifuge tubes were now placed under each SPE cartridge. Cartridges were 
eluted with 500 µL of methanol, which is collected into the clean 1.5 mL tube. Samples 
were evaporated in a 65˚C bead bath in a fume hood over-night. Once evaporated, samples 
were reconstituted with 500 µL of ELISA buffer (made up from Cayman Chemical kits). 
4.3.5b Analysis of steroids using ELISA kits 
 Estradiol, 11KT, and VTG kits were used according to the manufacturer’s 
guidelines. Briefly, an 8-point standard curve was prepared separately for the estradiol and 
11KT assays, while an 11-point standard curve was used for VTG assays. A standard curve 
with a r2 of 0.99 or greater was deemed acceptable for use in the assay. Three biological 
replicates with three technical replicates each were run per treatment, per sex. An example 
of plate setup for estradiol and 11kT plates can be found in Figure 4.1, with an example of 
VTG plate setup found in Figure 4.2. Once all necessary reagents were added to ELISA 
plates, the plates were incubated. Estradiol ELISA plates were incubated for one hour on 
an orbital shaker, set at low speed, at room temperature (20-25˚C). After incubation, 
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estradiol plates were rinsed 5 times with Wash Buffer, then 200 µL of Ellman’s Reagent 
was added to each well. Finally 5 µL of tracer was added to the TA well, then plates were 
covered with plastic film, wrapped in foil, and allowed to develop for 90 minutes using an 
orbital shaker, set at low speed. For the 11KT ELISA assays, after all reagents were added, 
the plate was incubated at 4˚C for 18 hours. After the 18 hours, the wells were emptied and 
rinsed 5 times with Wash Buffer, then 200 µL of Ellman’s Reagent was added to each well. 
Finally 5 µL of tracer was added to the TA well, then plates were covered with plastic film, 
wrapped in foil, and allowed to develop for 120 minutes using an orbital shaker. For both 
the estradiol and 11KT assays, once development of the plate was finished, the bottom of 
the plate was wiped off using a Kimwipe®, the plastic film was carefully removed from 
the plate, and the plate was read on a Synergy™ HT Multi-Detection Microplate Reader 
by Bio-Tek®, at a wavelength of 412 nm. Estradiol and 11KT analysis was performed 
using Cayman Chemical data reduction software from the Cayman Chemical website.  
 For the VTG analysis, only male samples were run to determine if metformin and 
guanylurea caused endocrine disrupting effects in male medaka. After all reagents were 
added to the plate (pictured in Figure 4.2), plates were sealed with plastic film and 
incubated at room temperature for 1 hour. After incubation, wells were emptied and washed 
three times with Wash Buffer (from VTG kits), then 100 µL of diluted detecting antibody 
was added to all wells. Plates were again sealed with plastic film and allowed to incubate 
at room temperature for 1 hour. To develop plates, the plastic film was removed and plates 
were washed five times with Wash Buffer, then 100 µL of TMB Substrate (from VTG kits) 
was added to each well. Plates were wrapped in foil and incubated at room temperature for 
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an additional 15 minutes. After 15 minutes, the reaction was stopped by adding 100 µL of 
0.3M H2SO4 to each well. Once the reaction was stopped, the bottom of the plate was wiped 
off using a Kimwipe®, the plastic film was carefully removed from the plate, and the plate 
was read on a Synergy™ HT Multi-Detection Microplate Reader by Bio-Tek®, at a 
wavelength of 450 nm. VTG results were analyzed by first calculating the NSB-corrected 
absorbance by subtracting the mean of the NSB wells from each of the samples, including 
the standard curve. The absorbance values for the standards were plotted against the VTG 
concentration, and a regression analysis was performed by a linear curve fit, where an r2 
value of 0.99 or higher was deemed acceptable. The mean of the NSB-corrected absorbance 
values for each set of sample duplicates was calculated. Here, only samples that fall within 
the standard curve working range were used. The mean NSB-corrected absorbance values 
were divided by the weight of each liver to get the amount of VTG in ng/mg of liver. 
Directions for equations can be found in section K. Calculation of Results on page 11 of 





Figure 4.1: Estradiol and 11keto-Testosterone example plate setup from Cayman Chemical 





Figure 4.2: Vitellogenin example plate setup from Cayman Chemical Vitellogenin ELISA 




4.3.6 Statistical analysis 
 All data were analyzed using SigmaPlot (Systat Software Inc.). Normality of all 
data was confirmed using a Shapiro-Wilk test prior to subsequent statistical analysis. 
Treatment effects on growth (length, wet weight, condition factor, HSI, and GSI), and 
steroid expression in livers of treated and untreated males and females were determined 
using a 1-way ANOVA, followed by a Dunnett post-hoc test. Average growth parameters 
were used to generate a replicate mean, and replicate means were further averaged to 
generate treatment means to give an n of 3. Cumulative egg output data was first 
normalized based on reproductive females, then a one-way analysis of covariance 
(ANCOVA) followed by a Bonferroni post hoc analysis to determine significance. An α of 
0.05 was used to determine statistical significance for all tests. Determination of 
waterborne metformin and guanylurea concentrations in the life-cycle study were again 
performed at the Water Quality Center at Trent University (Peterborough, Ontario, CA) in 
the same manner mentioned in 2.3.2d Metformin determination. Measured waterborne 
concentrations are shown in Table 4.1. Because levels of 1.0 ng·L-1 guanylurea are below 
the machine’s limit of detection, contents of the brown stock bottle were analyzed for 




Table 4.1 Nominal and mean concentrations (± standard error) of metformin and 
guanylurea as measured by liquid chromatography-mass spectrometry. Mixture = 3.2 µg·L-
1 metformin + 7.5 µg·L
-1 guanylurea.  
Nominal concentration 
µg·L-1  
Mean measured metformin 
(µg·L-1; SE) 
Mean measured guanylurea 
(µg·L-1; SE) 
Control < 0.25 <0.25 
0.001 Guanylurea < 0.25 1.25 (0.115)*(stock 
solution) 
7.5 Guanylurea < 0.25 6.85 (0.239) 
3.2 Metformin 3.22 (0.237) < 0.25 






4.4.1 Percent mortality, hatch success, and time-to-hatch 
 There was no significant difference observed in percent mortality (ANOVA DF = 
4, F = 1.20, p >0.05), hatch success (ANOVA DF = 4, F = 0.64, p > 0.05), or time-to-hatch 
(ANOVA DF = 4, F = 1.66, p > 0.05) in medaka embryos exposed to any of the 
experimental treatments, relative to controls (Table 4.2). Similarly, no developmental 




Table 4.2 Percent larval mortality, percent hatch success, and mean time to hatch (± 
standard mean) for medaka exposed to metformin and guanylurea for 165 days. Mixture = 








Time to hatch  
(days, ±SE) 
Control 15.0 (0.180) 86.9 (0.840) 8.89 (0.042) 
1.0 ng ·L-1 guanylurea 12.5 (0.338) 85.0 (0.926) 8.77 (0.043) 
7.5 µg·L-1 guanylurea 12.7 (0.236) 86.2 (1.40) 8.77 (0.044) 
3.2 µg·L-1 metformin 15.0 (0.077) 91.3 (0.596) 8.75 (0.043) 





4.4.2 Size and condition factor 
  No significant growth differences were seen in male Japanese medaka exposed to 
any treatment concentration compared to control males (weight: DF = 4, F = 1.81, p = 
0.204, Figure 4.3A; length: DF = 4, F = 2.75, p = 0.088, Figure 4.3B; condition factor: DF 
= 4, F = 0.681, p = 0.621, Figure 4.4). Male medaka mean weight, length, and condition 
factor can be found in Table 4.3. Similarly, no significant difference in female medaka 
growth was seen when compared to control females (weight: DF = 4, F = 1.76, p = 0.213, 
Figure 4.5A; length: DF = 4, F = 1.53, p = 0.266, Figure 4.5B; condition factor: DF = 4, F 
= 0.751, p = 0.581, Figure 4.6). Mean weight, length, and condition factor for female 




Table 4.3: Mean weight, length, and condition factor (K) for adult male medaka exposure 
to metformin and guanylurea for 165 days. Mixture = 3.2 µg· L-1 metformin + 7.5 µg · L-1 
guanylurea (n = 3).  
Concentration 
 




Mean K  
(±SE) 
Control 412.0 (26.7) 33.5 (0.454) 1.08 (0.029) 
1.0 ng ·L-1 guanylurea 389.0 (8.71) 33.3 (0.225) 1.04 (0.006) 
7.5 µg·L-1 guanylurea 375.0 (6.21) 32.7 (0.270) 1.07 (0.014) 
3.2 µg·L-1 metformin 364.0 (14.8) 32.5 (0.190) 1.08 (0.011) 






Figure 4.3: Mean male wet weight (A) and length (B) of 165 day old adult Japanese medaka (± SE) by treatment concentration 







Figure 4.4: Mean condition factor of 165 day old adult Japanese medaka (± SE) by 




Table 4.4: Mean weight, length, and condition factor (K) for adult female medaka exposure 
to metformin and guanylurea for 165 days. Mixture = 3.2 µg· L-1 metformin + 7.5 µg · L-1 
guanylurea (n = 3).  
Concentration 
 




Mean K  
(±SE) 
Control 449.0 (5.31) 33.9 (0.398) 1.16 (0.022) 
1.0 ng ·L-1 guanylurea 472.0 (12.0) 34.6 (0.124) 1.14 (0.021) 
7.5 µg·L-1 guanylurea 415.0 (10.8) 33.2 (0.312) 1.14 (0.012) 
3.2 µg·L-1 metformin 411.0 (25.5) 33.6 (0.647) 1.08 (0.052) 





Figure 4.5: Mean female wet weight (A) and length (B) of 165 day old adult Japanese medaka (± SE) by treatment concentration 







Figure 4.6: Mean female condition factor of 165 day old adult Japanese medaka (± SE) by 




4.4.3 Hepatosomatic index and gonadosomatic index 
 No significant effects of any treatment on male fish HSI was observed (DF = 4, F 
= 1.86, p = 0.197, Figure 4.7). Similarly, no significant effects of exposure treatments were 
seen on female HSI (DF = 4, F = 0.781, p = 0.563, Figure 4.8A) or GSI (DF = 4, F = 2.39, 





Figure 4.7: Mean male hepatosomatic index of 165 day old adult Japanese medaka (± SE) 










Figure 4.8: Mean female hepatosomatic index (A) and gonadosomatic index (B) of 165 day old adult Japanese medaka (± SE) 
by treatment concentration (n = 3). Mixture = 3.2 µg· L-1 metformin + 7.5 µg · L-1 guanylurea.
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4.4.4 Steroid hormone analysis 
 A significantly higher production of estradiol was seen in the liver of male medaka 
exposed to 7.5 µg · L-1 guanylurea (DF = 4, F = 6.20, p = 0.011, Figure 4.9) when compared 
to control males, however no other experimental treatment caused a significant effect in 
estradiol production. Additionally, livers of male medaka exposed to the mixture treatment 
showed a significant increase in the production of 11-KT (DF = 4, F = 5.76, p = 0.014, 
Figure 4.10) when compared to control males, while no significant effect of treatment on 
the concentration of VTG was seen (DF = 4, F = 4.02, p = 0.069, Figure 4.11). No significant 
difference in the production of estradiol was found in the liver of adult female medaka at 
any experimental treatment (DF = 4, F = 2.71, p = 0.057, Figure 4.12), while a significant 
increase in the production of 11KT was seen in the liver of females exposed to 3.2 µg · L-1 





Figure 4.9: Mean estradiol production in adult male Japanese medaka livers (± SE) by 
treatment concentration (n = 3). Mixture = 3.2 µg· L-1 metformin + 7.5 µg · L-1 guanylurea. 





Figure 4.10: Mean 11-keto testosterone (11KT) production in adult male Japanese medaka 
livers (± SE) by treatment concentration (n = 3). Mixture = 3.2 µg· L-1 metformin + 7.5 µg 





Figure 4.11: Mean vitellogenin (VTG) concentration in adult male Japanese medaka livers 
(± SE) by treatment concentration (n = 3). Mixture = 3.2 µg· L-1 metformin + 7.5 µg · L-1 





Figure 4.12: Mean estradiol production in adult female Japanese medaka livers (± SE) by 
treatment concentration (n = 3). Mixture = 3.2 µg· L-1 metformin + 7.5 µg · L-1 guanylurea. 





Figure 4.13: Mean 11-keto testosterone (11KT) production in adult female Japanese medaka 
livers (± SE) by treatment concentration (n = 3). Mixture = 3.2 µg· L-1 metformin + 7.5 µg 




4.4.5 Reproductive effects 
 Results from a 2-way ANCOVA showed that there is no interaction between 
experiment treatment and egg collection per day (DF = 4, F = 0.151, p = 0.962). Similarly, 
and despite the significant effects seen in adult medaka growth and steroid production, no 
significant effects were seen in reproductive output for any of the experiment treatments 
(DF = 4, F = 1.10, p = 0.359, Figure 4.14). However, an analysis of the equal slopes model 
showed that there is a significant difference in the slopes of the 1.0 ng· L-1 guanylurea and 
3.2 µg· L-1 metformin experimental treatment groups when compared to the control group 
(DF = 4, F = 5.34, p < 0.001), indicating that a longer collection period would potentially 





Figure 4.14: Cumulative reproductive output normalized to reproductive by treatment 
concentration (n = 14 control females; 3, 3.2 µg· L-1 metformin females; remainder of the 
treatments contained 9 reproductive females each). Cumulative egg data spans 10 collection 
days. Data points represent the replicate means per treatment (Data with error bars can be 





 These results demonstrated that while environmentally relevant concentrations of 
metformin, and its metabolite, guanylurea, do not cause measurable impacts on the growth 
of adult Japanese medaka, they do have effects on the steroid hormone production in 
exposed adult fish. The results seen here for metformin exposure do not specifically 
corroborate the results seen by Niemuth and Klaper (2016) which showed a significant 
decrease in weight of metformin treated male FHM. Niemuth and Klaper (2016) also 
observed a significant reduction in the condition factor of metformin treated males, while 
no significant difference was observed in male medaka condition factor in the present study. 
This could be due to the relatively small sample size (n = 3) at the close of the current study. 
Adult male medaka are notoriously aggressive especially in response to feeding (Ruzzante 
and Doyle, 1991). In our study in particular, male medaka were wounding other males and 
females, resulting in occasional mortality. Although not significant, the growth of male 
medaka exposed to metformin and guanylurea appeared to be more sensitive than females, 
in the current study. This trend does corroborate the results seen by Niemuth and Klaper 
(2016), which showed a significant decrease in the weight of metformin treated male FHM, 
while females showed no effect. It should be pointed out that the Niemuth and Klaper (2016) 
used an experimental treatment of 40 µg · L-1, which is 12.5 times the concentration used in 
the present study of 3.2 µg · L-1 metformin. These combined results suggest that metformin 
may be taken up by males more readily than females. However, our metformin uptake 
results demonstrate that there is comparable uptake of metformin by both sexes at the larval 




 No significant effect was seen in the HSI of male and female medaka for any 
treatment concentration. Similarly, no significant effect was seen in the GSI of female 
medaka for any treatment concentration, however female medaka exposed to 3.2 µg · L-1 
showed high variability in gonad weight, and thus GSI (Figure 4.7), which could explain 
the lack of significance. Unlike previous results in the literature, the present study did not 
observe effects on the concentration of the protein VTG in exposed male livers at any 
treatment concentration, where-as a 30-fold overexpression in VTG in exposed male FHM 
was seen in Niemuth et al. (2015). Again, this could be due to the differing exposure 
concentrations, or differing methods in the measurement of VTG. VTG concentration was 
measured in the plasma of male FHM, while the present study utilized male medaka livers 
because of the extremely small volume of blood that can be removed from medaka.  
 Interestingly, male medaka exposed to 7.5 µg · L-1 guanylurea produced 
significantly more estradiol, while males exposed to a mixture of the two compounds (3.2 
µg · L-1 + 7.5 µg · L-1) produced significantly more 11KT when compared to control males. 
It appears that metformin and guanylurea act in an antagonistic manner on the production 
of estradiol in male medaka (Figure 4.8), while the compounds act in an additive manner on 
the production of 11KT (Figure 4.9). Although the results were not significant, metformin 
and guanylurea appeared to act in a synergistic manner on the production of estradiol in 
female medaka (Figure 4.11). Of particular interest is the significantly increased production 
of 11KT in female medaka exposed to 3.2 µg · L-1 metformin, as the pharmaceutical was 
shown to decrease circulating androgen levels in human females with polycystic ovary 
syndrome (Earle, 2000). The effect of a mixture of metformin and guanylurea on 11KT 
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production in female medaka also appears to be extremely antagonistic, with females 
exposed to the mixture producing 11KT levels similar to that of controls (Figure 4.12).   
 Despite significant effects seen in steroid hormone production, no significant effects 
were seen in reproductive output of Japanese medaka exposed to environmentally relevant 
concentrations of metformin and guanylurea, alone, or in combination. This differs from 
results found in the literature which showed a significant decrease in the number of 
cumulative egg clutches produced by metformin exposed mating FHM pairs when 
compared to controls (Niemuth and Klaper, 2016). Although the reproductive output 
findings in the present research were not significant, an analysis of the equal slopes model 
shows that there is a difference in the slope of the lines plotting the cumulative egg 
production per day for medaka exposed to 1.0 ng · L-1 guanylurea (increased production) 
and 3.2 µg · L-1 metformin (decreased production). These merely show a trend, and future 
















5.1 General conclusions 
 This dissertation aimed to investigate the effects associated with metformin and 
guanylurea exposure to two critical life stages of Japanese medaka. The results 
demonstrated that these common surface water contaminants have a measurable impact on 
the growth of early-life stage medaka, while they have a potential impact on the growth of 
male adult medaka. To date, this is the first study to investigate and show that metformin 
can be taken up and transiently stored in embryo and larval medaka. This finding is 
extremely important, as it provides confirmation that the effects of metformin reported both 
in the literature and in this thesis are likely due to compound uptake. Although the uptake 
of guanylurea was not addressed in this research, due to the similar chemical structure to its 
parent compound, it is plausible that it also can be taken up by fish, thus providing insight 
into the effects of guanylurea on larval growth.    
Interestingly, waterborne metformin uptake and accumulation was dependent on 
chorion hardening in the present study, with hardening appearing to completely prevent 
uptake.  This may indicate that windows of sensitivity exist for embryos exposed to 
metformin in aquatic ecosystems prior to chorion hardening.  Stages 1 through 11 of medaka 
development fall within the first 8 hours after fertilization (pre-chorion hardening), which 
encompass the early through late blastula stages (Iwamatsu, 2004). Exposure during these 
stages may have implications for early cell division, or incomplete meiosis, leading to a 
failure in embryo development (Iwamatsu, 2004). This study also showed that when both 
embryos and larvae were exposed to 14C-metformin, followed by a short 24-h depuration, 
all of the detectable metformin was depurated out of the embryo and larvae.  
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Metformin and guanylurea exposure over a 28-day period resulted in significantly 
stunted growth in both male and female medaka at environmentally relevant concentrations, 
with significant effects observed in exposure concentrations as low as 3.2 µg · L-1 metformin 
and 1.0 ng · L-1 guanylurea. Decreased size in 28 day old fish exposed to metformin and 
guanylurea may be attributed to disruptions in cellular pathways involved in growth and cell 
proliferation, as seen by significant changes in metabolite response factors and the altered 
gene expression in exposed larvae. It should be noted that gene expression is a snap-shot of 
the expression at the moment of sampling, and it is possible that metformin and guanylurea 
altered the expression of the genes of interest during critical growth periods that were not 
measured here. Additionally, the genes of interest were chosen based on metabolomics 
findings and feasibility, however it would be advantageous for future research to pair 
metabolomics with transcriptomics and proteomics to gain insight on the full organism 
effects of metformin and guanylurea.  
While the full life-cycle exposure to environmentally relevant concentrations of 
metformin and guanylurea alone, and in combination, did not results in a statistically 
significant impact on growth, steroid hormone production in adult Japanese medaka was 
significantly affected. Additionally, no significant effects in HSI for male medaka was seen, 
and no significant effect in female HSI or GSI was seen. However, this could be explained 
by the large variability seen in gonad weight between females.  
The combination of metformin and guanylurea act in an antagonistic manner on the 
production of estradiol in male medaka, while the compounds act in an additive manner on 
the production of 11KT. Of particular interest is the significantly increased production of 
11KT in female medaka exposed to 3.2 µg · L-1 metformin, as the pharmaceutical is used to 
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decrease circulating androgen levels in human females with polycystic ovary syndrome. 
Additionally, combination effects of metformin and guanylurea on 11KT production appear 
to be extremely antagonistic in female medaka.  
Despite the significant effects seen in steroid hormone production, no significant 
effects were seen in the reproductive output of Japanese medaka exposed to environmentally 
relevant concentrations of metformin and guanylurea, alone, or in combination. 
Additionally, no effect was seen in the production of VTG in male medaka in any of the 
experimental treatments. Again, it would be advantageous for future work to investigate the 
potential transcriptomic and proteomic effects in metformin and guanylurea exposed adult 
fish. This would better help explain the interesting effects seen in this research.  
Overall, our findings demonstrate the need for further research into the effects of 
metformin and its metabolite guanylurea on non-target aquatic organisms. These results are 
novel, as there have been no previous studies addressing these endpoints in this manner in 
fish. This thesis has significantly contributed to the knowledge regarding the effects of 
metformin and guanylurea and has successfully filled in some of the current gaps in the 
literature. It is apparent from this research that environmentally relevant concentrations of 
both compounds cause alterations in the cellular function of Japanese medaka. Field studies 
should also be performed to elucidate their possible effects on wild fish populations in 
receiving waters. This would help to tease out which life-stage is most sensitive, and offer 
new insights on potential population-level impacts. Considering that surface waters will 
likely continue to have increasing concentrations of metformin and guanylurea, gaining new 
















Abdullah, M., Kornegay, J.N., Honcoop, A., Parry, T.L., Balog-alvarez, C.J., Id, 
S.K.O.N., Bain, J.R., Muehlbauer, M.J., Newgard, C.B., Patterson, C., Willis, M.S., 
2017. Non-Targeted Metabolomics Analysis of Golden Retriever Muscular 
Dystrophy-Affected Muscles Reveals Alterations in Arginine and Proline 
Metabolism, and Elevations in Glutamic and Oleic Acid In Vivo. Metabolites. 7: 1–
19. 
Adibhatla, R.M., Hatcher, J.F., Sailor, K., Dempsey, R.J., 2002. Polyamines and central 
nervous system injury: spermine and spermidine decrease following transient focal 
cerebral ischemia in spontaneously hypertensive rats. Brain Research. 938: 81-86. 
Akoh, Casimir C., David B. Min. Food Lipids: Chemistry, Nutrition, and Biotechnology. 
CRC Press, 2002. Print. 
Ardrey RE. 2003. Liquid Chromatography–Mass Spectrometry: An Introduction. John 
Wiley, West Sussex, UK. 
Arsson, D.G.J.O.L., 2009. Pharmaceuticals and Personal Care Products in the 
Environment Contamination of Surface, Ground, and Drinking Water. Environ 
Toxicol Chem. 28, 2522–2527. 
Aster J, Kumar V, Robbins SL, Abbas AK, Fausto N, Cotran RS. Pathologic Basis of 
Disease. Saunders/Elsevier. 2010. Print. ISBN 1-4160-3121-9. 
Baenke, F., Peck, B., Miess, H., Schulze, A., 2013. Hooked on fat: the role of lipid 
synthesis in cancer metabolism and tumour development. Disease Models and Mech. 
1363, 1353–1363. doi:10.1242/dmm.011338 
Balch, G.C., Shami, K., Wilson, P.J., Wakamatsu, Y., Metcalfe, C.D., 2004. Feminization 
of female leukophore-free strain of Japanese medaka (Oryzias latipes) exposed to 
17β-estradiol. Environ Toxicol Chem. 23(11): 2763-2768. 
Becker, M.L., Visser, L.E., van Schaik, R.H.N., Hofman,  a, Uitterlinden,  a G., Stricker, 
B.H.C., 2009. Genetic variation in the organic cation transporter 1 is associated with 
138 
 
metformin response in patients with diabetes mellitus. Pharmacogenomics J. 9: 242–
7. doi:10.1038/tpj.2009.15 
Berker, B., Emral, R., Demirel, C., Corapcioglu, D., Unlu, C., Kose, K., 2004. Increased 
insulin-like growth factor-I levels in women with polycystic ovary syndrome, and 
beneficial effects of metformin therapy. Gynecol Endocrinol 19: 125–133. 
doi:10.1080/09513590400007309 
Bjorklund, M. A. et al. Non-CDK-bound p27 (p27(NCDK)) is a marker for cell stress and 
is regulated through the Akt/PKB and AMPK-kinase pathways. Exp. Cell Res. 316: 
762–774 (2010). 
Blair, B.D., Crago, J.P., Hedman, C.J., Treguer, R.J.F., Magruder, C., Royer, L.S., Klaper, 
R.D., 2013. Science of the Total Environment Evaluation of a model for the removal 
of pharmaceuticals, personal care products, and hormones from wastewater. Sci. 
Total Environ. 444: 515–521. doi:10.1016/j.scitotenv.2012.11.103 
Boxall, A.B., Rudd, M.A., Brooks, B.W., Caldwell, D.J., Choi, K., Hickmann, S., Innes, 
E., Ostapyk, K., Staveley, J.P., Verslycke, T., Ankley, G.T., Beazley, K.F., Belanger, 
S.E., Berninger, J.P., Carriquiriborde, P., Coors, A., Deleo, P.C., Dyer, S.D., Ericson, 
J.F., Gagne, F., Giesy, J.P., Gouin, T., Hallstrom, L., Karlsson, M. V, Larsson, D.G., 
Lazorchak, J.M., Mastrocco, F., McLaughlin, A., McMaster, M.E., Meyerhoff, R.D., 
Moore, R., Parrott, J.L., Snape, J.R., Murray-Smith, R., Servos, M.R., Sibley, P.K., 
Straub, J.O., Szabo, N.D., Topp, E., Tetreault, G.R., Trudeau, V.L., Van Der Kraak, 
G., 2012. Pharmaceuticals and personal care products in the environment: what are 
the big questions? Env. Heal. Perspect. 120: 1221–1229. doi:10.1289/ehp.1104477 
Bridges, K., Venables, B., Roberts, A., 2017. Effects of dietary methylmercury on the 
dopaminergic system of adult fathead minnows and their offspring. Enviro Toxicol 
Chem. 36, 1077-1084. 
139 
 
Bridges, K.N., Soulen, B.K., Overturf, C.L., Drevnick, P.E., Roberts, A.P., 2016. 
Embryotoxicity of maternally‐transferred methylmercury to fathead minnows 
(Pimephales promelas). Environ Toxicol and Chem. 35, 1436-1441 
Bridges, K.N., Zhang, Y., Curran, T.E., Magnuson, J.T., Venables, B.J., Durrer, K.E., 
Allen, M., Roberts, A.P. (Accepted 04/27/2018). Alterations to the intestinal 
microbiome and metabolome of Pimephales promelas and Mus musculus following 
exposure to dietary methylmercury. Environmental Science & Technology. 
Brooks, B.W., Foran, C.M., Richards, S.M., Weston, J., Turner, P.K., Stanley, J.K., 
Solomon, K.R., Slattery, M., La Point, T.W., 2003. Aquatic ecotoxicology of 
fluoxetine. Toxicol. Lett. 142: 169–183. doi:10.1016/S0378-4274(03)00066-3 
Carius, A., Grüttner, G. Pharmaceuticals in the - environment – the global perspective 
occurrence, effects, and potential cooperative action under SAICM. 2014. Print. 
http://www.pharmaceuticals-in-the-environment.org 
Celiz, M.D., Tso, J., Aga, D.S., 2009. Pharmaceutical metabolites in the environment: 
analytical challenges and ecological risks. Env. Tox and Chem. 28: 2473-2484.   
Corcoran, J., Winter, M.J., Tyler, C.R., 2010. Pharmaceuticals in the aquatic environment: 
a critical review of the evidence for health effects in fish. Crit. Rev. Toxicol: 40, 287–
304. doi:10.3109/10408440903373590 
Crago, J., Bui, C., Grewal, S., Schlenk, D., 2016. Age-dependent effects in fathead 
minnows from the anti-diabetic drug metformin. Gen. Comp. Endocrinol. 
doi:10.1016/j.ygcen.2015.12.030 
Crowder, L.B., Rice, J.A., Miller, T.J. Individual-based Models and Approaches in 
Ecology: Emperical and theoretical approaches to size-based interactions and 
recruitment variability in fishes. Chapman and Hall, New York. 1992. Print. 
Danielson, PB. 2002. The cytochrome P450 superfamily: Bio- chemistry, evolution and 
drug metabolism in humans. Curr Drug Metab 3:561–597. 
140 
 
Earle, T., 2000. Review Articles. Cambridge Archaeol. J. 1: 187–205. 
doi:10.1080/00048623.1992.10754800-1 
Ercal, B., Crawford, P.A., Fetal and Neonatal Physiology (Fifth Edition), 2017. Print. 
Endo, M., Oyadomari, S., Terasaki, Y., Takeya, M., Suga, M., Mori, M., Gotoh, T., 
Oyadomari, S., Ter-, Y., Takeya, M., Suga, M., 2003. Induction of arginase I and II 
in bleomycin-induced fibrosis of mouse lung. Am J Physiol Lung Cell Mol Physiol. 
285: 313–321. 
Fasulo, S., Iacono, F., Cappello, T., Corsaro, C., Maisano, M., Agata, A.D., Giannetto, A., 
Domenico, E. De, Parrino, V., Lo, G., Mauceri, A., 2012. Ecotoxicology and 
Environmental Safety Metabolomic investigation of Mytilus galloprovincialis ( 
Lamarck 1819 ) caged in aquatic environments. Ecotox and Env Safety. 84: 139–146. 
Fatta-Kassinos, D., Meric, S. & Nikolaou, A. 2011. Pharmaceutical residues in 
environmental waters and wastewater: current state of knowledge and future 
research. Anal Bioanal Chem 399: 251. https://doi.org/10.1007/s00216-010-4300-9 
Fink-Jensen, A., Vilsbøll, T., 2016. Glucagon-like peptide-1 (GLP-1) analogues: A 
potential new treatment for alcohol use disorder? Nord. J. Psychiatry. 9488, 1–2. 
doi:10.1080/08039488.2016.1176252 
Fischer, S., Klüver, N., Burkhardt-Medicke, K., Pietsch, M., Schmidt, A., Wellner, P., 
Schirmer, K., Luckenbach, T., 2013. Abcb4 acts as multixenobiotic transporter and 
active barrier against chemical uptake in zebrafish (Danio rerio) embryos. BMC 
Biology 11:69. 
Flippin, J.L., Huggett, D., Foran, C.M., 2007. Changes in the timing of reproduction 
following chronic exposure to ibuprofen in Japanese medaka, Oryzias latipes. Aquat. 
Toxicol. 81: 73–78. doi:10.1016/j.aquatox.2006.11.002 
Foran, C.M., Weston, J., Slattery, M., Brooks, B.W., Huggett, D.B., 2003. Reproductive 
assessment of Japanese medaka (Oryzias latipes) following a four-week fluoxetine 
(SSRI) exposure. Arch. Environ. Contam. Toxicol. 46: 511-517. 
141 
 
Gagnon, J., Sheppard, E., Anini, Y., 2013. Metformin directly inhibits ghrelin secretion 
through AMP-activated protein kinase in rat primary gastric cells. Diabetes. Obes. 
Metab. 15, 276–9. doi:10.1111/dom.12021 
Galardo, N., Pellizzari, E.H., Meroni, S.B., Cigorraga, S.B., 2009a. Molecular 
mechanisms involved in Sertoli cell adaptation to glucose deprivation. Am J Physiol 
Endocrinol Metab 297: 907–914. doi:10.1152/ajpendo.00235.2009 
Galardo, N., Pellizzari, E.H., Meroni, S.B., Cigorraga, S.B., Shackelford, D.B., Shaw, 
R.J., Shu, Y., Sheardown, S. a S., Brown, C., Owen, R.P., Zhang, S., Castro, R. a, 
Ianculescu, A.G., Yue, L., Lo, J.C., Burchard, E.G., Brett, C.M., Giacomini, K.M., 
Tang, T., Jm, Lord, Rj, N., Yasmin, E., Ah, B., Zhou, G., Myers, R., Li, Y., Chen, Y., 
Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., 
Hirshman, M.F., Goodyear, L.J., Moller, D.E., 2009b. Effect of genetic variation in 
the organic cation transporter 1 (OCT1) on metformin action. J. Clin Invest. 117: 
563–575. doi:10.1172/JCI30558DS1 
Ghoshdastidar, A.J., Fox, S., Tong, A.Z., 2015. The presence of the top prescribed 
pharmaceuticals in treated sewage effluents and receiving waters in Southwest Nova 
Scotia , Canada. Environ Sci Pollut Res.22: 689–700. doi:10.1007/s11356-014-3400-z 
Glueck, C.J., Bornovali, S., Pranikoff, J., Goldenberg, N., Dharashivkar, S., Wang, P., 
2004. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic 
ovary syndrome. Diabet. Med. 21: 829–836. doi:10.1111/j.1464-5491.2004.01251.x 
Gong, L., Goswamic, S., Giacominic, K.M., Altmana R.B., Klein, T.E. 2012. Metformin 
pathways: pharmacokinetics and pharmacodynamics. Pharma Geno. 22: 820–827. 
doi:10.1097/FPC.0b013e3283559b22 
Goodyear, L.J., Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-melody, J., Wu, 
M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M.F., Goodyear, L.J., 
Moller, D.E., 2001. Role of AMP-Activated Protein Kinase in Mechanism of 
Metformin Action Role of AMP-activated protein kinase in mechanism of metformin 
142 
 
action. J. Clin Invest. 108: 1167–1174. doi:10.1172/JCI13505 
Harris, I.R., Höppner, H., Siefken, W., Farrell, A.M., Wittern, K.P., 2000. Regulation of 
HMG-CoA Synthase and HMG-CoA Reductase by Insulin and Epidermal Growth 
Facter in HaCaT Keratinocytes. J. Invest. Dermatol. 114: 83-87 
Hawley, S.A., Ross, F.A., Chevtzoff, C., Green, K.A., Evans, A., Fogarty, S., Towler, 
M.C., Brown, L.J., Ogunbayo, O.A., Evans, A.M., Hardie, D.G., 2010. Resource Use 
of Cells Expressing g Subunit Variants to Identify Diverse Mechanisms of AMPK 
Activation. Cell Metab. 11: 554–565. doi:10.1016/j.cmet.2010.04.001 
Hernández, B., Pflüger, F., Kruglik, S.G., Cohen, R., Ghomi, M., 2015. Journal of 
Pharmaceutical and Biomedical Analysis Protonation – deprotonation and structural 
dynamics of antidiabetic drug metformin. J. Pharm. Biomed. Anal. 114: 42–48. 
doi:10.1016/j.jpba.2015.04.041 
Holford NHG. Pharmacokinetics and pharmacodynamics: Rational dosing and the time 
course of drug action. In: Katzung BG, ed. Basic and Clinical Pharmacology New 
York, USA: McGraw-Hill Professional, pp 24-50. 2001. Print. 
Huggett, D.B., Brooks, B.W., Peterson, B., Foran, C.M., Schlenk, D., 2002. Toxicity of 
select beta adrenergic receptor-blocking pharmaceuticals (B-blockers) on aquatic 
organisms. Arch. Environ. Contam. Toxicol. 43: 229–235. doi:10.1007/s00244-002-
1182-7 
Igel, L.I., Sinha, A., Saunders, K.H., Apovian, C.M., Vojta, D., Aronne, L.J., 2016. 
Metformin: an Old Therapy that Deserves a New Indication for the Treatment of 
Obesity. Curr. Atheroscler. Rep. 18: 16. doi:10.1007/s11883-016-0568-3 
IMS Health. www.imshealth.com. Last accessed October 2016 
Iwamatsu, T., 2004. Stages of normal development in the medaka, Oryzias latipes. Mech 
Dev. 121: 605–618. doi:10.1016/j.mod.2004.03.012 
Johns, S.M., Denslow, N.D., Kane, M.D., Watanabe, K.H., Orlando, E.F., Sepúlveda, 
M.S., 2011. Effects of estrogens and antiestrogens on gene expression of fathead 
minnow (Pimephales promelas) early life stages. Environ. Toxicol. 26: 195-206. 
143 
 
Jones, O.A.H., Voulvoulis, N., Lester, J.N., 2002. Aquatic environmental assessment of 
the top 25 English prescription pharmaceuticals. Water Res. 36: 5013–5022. 
doi:10.1016/S0043-1354(02)00227-0 
Kahn, B.B., Alquier, T., Carling, D., Hardie, D.G., 2005. AMP-activated protein kinase: 
Ancient energy gauge provides clues to modern understanding of metabolism. Cell 
Metab. 1: 15–25. doi:10.1016/j.cmet.2004.12.003 
Khan, S.J., Ongerth, J.E., 2004. Modelling of pharmaceutical residues in Australian 
sewage by quantities of use and fugacity calculations. Chemosphere. 54: 355–367. 
doi:10.1016/j.chemosphere.2003.07.001 
Khan, S.A., Liu, X., Li, H., Zhu, Y., Fan, W., Zhou, P., Rehman, Z. ur., 2016. 1H NMR-
based serum metabolic profiling of Carassius auratus gibelio under the toxicity of 
Pb2+ and Cd2+. Int. J. Environ. Sci. Technol. 13: 2597-2608. 
Khetan SK, Collins TJ. 2007. Human pharmaceuticals in the aquatic environment: A 
challenge to green chemistry. Chem Rev 107:2319–2364. 
Kidd, K.A., Blanchfield, P.J., Mills, K.H., Palace, V.P., Evans, R.E., Lazorchak, J.M., 
Flick, R.W., 2007. Collapse of a fish population after exposure to a synthetic 
estrogen. PNAS. 104: 8897–8901 
Kokushi, E., Shintoyo, A., Koyama, J., Uno, S., 2017. Evaluation of 2,4-dichlorophenol 
exposure of Japanese medaka, Oryzias latipes, using a meabolomics approach. 
Environ Sci Pollut Res. 24: 27678-27686 
Kolpin, D., Furlong, E., Zaugg, S., 2002. Pharmaceuticals, Hormones, and Other Organic 
Wastewater Contaminants in U.S. Streams , 1999-2000 : A National Reconnaissance 
1999–2000. USGS Fact Sheet FS-027-02. 
Lashen, H., 2010. Role of metformin in the management of polycystic ovary syndrome. 
Ther. Adv. Endocrinol. Metab. 1: 117–128. doi:10.1177/2042018810380215 
Le-minh, N., Khan, S.J., Drewes, J.E., Stuetz, R.M., 2010. Fate of antibiotics during 




Leonardi, R., Jackowski, S., 2016. Biosynthesis of Pantothenic Acid and Coenzyme A. 
EcoSal Plus. 2: 1–28 
Li Gonga, Srijib Goswamic, Kathleen M. Giacominic, Russ B. Altmana, b,  and T.E.K., 
2013. Metformin pathways: pharmacokinetics and pharmacodynamics. 
Pharmacogenet Genomics 22: 820–827. 
doi:10.1097/FPC.0b013e3283559b22.Metformin 
Li, Y. et al. 2011. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic 
steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13, 
376–388. 
Liao, P.H., Hwang, C.C., Chen, T.H., Chen, P.J., 2015. Developmental exposures to 
waterborne abused drugs alter physiological function and larval locomotion in early 
life stages of medaka fish. Aquat. Toxicol. 165: 84–92. 
doi:10.1016/j.aquatox.2015.05.010 
Lopaschuk, G.D., Ussher, J.R., Folmes, C.D., Jaswal, J.S. and Stanley, W.C., 2010. 
Myocardial fatty acid metabolism in health and disease. Physiol Rev. 90: 207-258. 
Lu, P., Takai, K., Weaver, V.M., Werb, Z., 2011. Extracellular Matrix Degradation and 
Remodeling in Development and Disease. Cold Spring Harb Perspect Biol. 1–24. 
Magi, E., Di Carro, M., Cristiana, M., Benedetti, B. 2016. Combining passive sampling 
and tandem mass spectrometry for the determination of pharmaceuticals and other 
emerging pollutants in drinking water. Microchem J. 136: 56-60. 
Magnoni, L.J., Vraskou, Y., Palstra, A.P., Planas, J. V., 2012. AMP-Activated protein 
kinase plays an important evolutionary conserved role in the regulation of glucose 
metabolism in fish skeletal muscle cells. PLoS One 7(2): 
doi:10.1371/journal.pone.0031219 
Malgorzata S., Marta, Z.C., Arleta, D., Dominika, M., Andrzej, S., Ewa, S., 2017. 
Prostaglandins , Leukotrienes and Essential Fatty Acids Metabolic pathways of oleic 
and palmitic acid are intensi fi ed in PCOS patients with normal androgen levels. 
Prostaglandins, Leukotrienes and Essential Fatty Acids 126: 105–111. 
145 
 
Marić, A., 2010. Metformin – More Than “ Gold Standard ” in the Treatment of Type 2 
Diabetes Mellitus. Dep. Intern. Med. 95–104. 
Medline Plus Drug Information: Estrogen and Progestin. https://medlineplus.gov. Last 
accessed October 2015 
Mihaylova, M.M., Shaw, R.J., 2011. The AMPK signalling pathway coordinates cell 
growth, autophagy and metabolism. Nat. Cell Biol. 13: 1016–23. 
doi:10.1038/ncb2329 
Miura, T., Higuchi, M., Ozaki, Y., Ohta, T., Miura, C., 2006. Progestin is an essential 
factor for the initiation of the meiosis in spermatogenetic cells of the eel. Proc. Natl. 
Acad. Sci. U. S. A. 103: 7333–7338. doi:10.1073/pnas.0508419103 
Mompelat S, LeBot B, Thomas O. 2009. Occurrence and fate of pharmaceutical products 
and by-products, from resource to drinking water. Environ Int 35:803–814. 
doi:10.1016/j.envint.2008.10.008 
Muller, C., Herberth, H., Cosquer, B., Kelche, C., Cassel, J.C., Schimchowitsch, S., 2007. 
Structural and functional recovery elicited by combined putrescine and 
aminoguanidine treatment after aspirative lesion of the fimbria-fornix and overlying 
cortex in the adult rat. European Journal of Neuroscience 25: 1949-1960. 
Nambiar, P.R.; Gupta, R.R.; Misra, V., 2010. An “Omics” based survey of human colon 
cancer. Mutat. Res. 693: 3–18. 
Nash, J.P., Kime, D.E., Van der Ven, L.T.M., Wester, P.W., Brion, F., Maack, G., 
Stahlschmidt-Allner, P., Tyler, C.R., 2004. Long-Term Exposure to Environmental 
Concentrations of the Pharmaceutical Ethynylestradiol Causes Reproductive Failure 
in Fish. Environ. Health Perspect. 112: 1725–1733. doi:10.1289/ehp.7209 
Niemuth, N.J., Jordan, R., Crago, J., Blanksma, C., Johnson, R., Klaper, R.D., 2015. 
Metformin exposure at environmentally relevant concentrations causes potential 
endocrine disruption in adult male fish. Environ. Toxicol. Chem. 34: 291–6. 
doi:10.1002/etc.2793 
Niemuth, N.J., Klaper, R.D., 2015. Emerging wastewater contaminant metformin causes 
146 
 
intersex and reduced fecundity in fish. Chemosphere 135: 38–45. 
doi:10.1016/j.chemosphere.2015.03.060 
Niemuth, N.J., Klaper, R.D., 2018. Low-dose metformin exposure causes changes in 
expression of endocrine disruption-associated genes. Aquat. Toxicol. 195: 33–40. 
doi:10.1016/j.aquatox.2017.12.003 
Nishiumi, S., Suzuki, M., Kobayashi, T., Matsubara, A., Azuma, T., Yoshida, M., 2014. 
Metabolomics for Biomarker Discovery in Gastroenterological Cancer. Metabolites. 
4: 547–571. doi:10.3390/metabo4030547 
Ofman, R., Dijkstra, I.M.E., Roermund, C.W.T. Van, Burger, N., Turkenburg, M., 
Cruchten, A. Van, Engen, C.E. Van, Wanders, R.J.A., Kemp, S., 2010. The role of 
ELOVL1 in very long-chain fatty acid homeostasis and X-linked 
adrenoleukodystrophy. EMBO Mol Med. 2: 90–97. doi:10.1002/emmm.201000061 
Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson 
A. 2006. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent 
inhibitor of CYP2C8: Implications for drug–drug interactions. Drug Metab Dispos 
34:191–197. 
Oosterhuis, M., Sacher, F., ter Laak, T.L., 2013. Prediction of concentration levels of 
metformin and other high consumption pharmaceuticals in wastewater and regional 
surface water based on sales data. Sci. Total Environ. 442: 380–388. 
doi:10.1016/j.scitotenv.2012.10.046 
Oulton, RL., Kohn, T., Cwiertney, DM., 2010. Pharmaceuticals and personal care 
products in effluent matrices: a survey of transformation and removal during 
wastewater treatment and implications for wastewater management. J Environ Monit. 
12: 1056-78 
Overturf, M.D., Anderson, J.C., Pandelides, Z., Beyger, L., Holdway, D., 2015. 
Pharmaceuticals and personal care products: A critical review of the impacts on fish 
reproduction. Crit. Rev. Toxicol. 8444: 1–23. doi:10.3109/10408444.2015.1038499 
Overturf, M.D., Huggett, D.B., 2015. Responses to various exposure durations of 
147 
 
levonorgestrel during early-life stages of fathead minnows (Pimephales promelas). 
Aquat. Toxicol. 161: 33–40. doi:10.1016/j.aquatox.2015.01.029 
Overturf, M.D., Overturf, C.L., Carty, D.R., Hala, D., Huggett, D.B., 2014. 
Levonorgestrel exposure to fathead minnows (Pimephales promelas) alters survival, 
growth, steroidogenic gene expression and hormone production. Aquat. Toxicol. 148: 
152–161. doi:10.1016/j.aquatox.2014.01.012 
Parenti, L.R., 2008. A phylogenetic analysis and taxonomic revision of rice fishes, 
Oryzias and relatives (Beloniformes, Adrianichthydae). Zool. J. Linn. Soc. 494–610. 
Parrott, J.L., Metcalfe, C.D., 2017. Assessing the effects of the antidepressant venlafaxine 
to fathead minnows exposed to environmentally relevant concentrations over a full 
life cycle. Environ Poll. 229: 403-411. 
Perry, D.K., Hannun, Y.A., 1998. The role of ceramide in cell signaling. Biochimica Et 
Biophysica Acta-Molecular and Cell Biology of Lipids. 1436: 233-243. 
Pentikäinen, P.J., Neuvonen, P.J., Penttilfi, A., Hc, I., 1979. Pharmacokinetics of 
Metformin After Intravenous and Oral Administration to Man. Eur J Clin 
Pharmacol. 202: 195–202. 
Polakof, S., Panserat, S., Craig, P.M., Martyres, D.J., Plagnes-Juan, E., Savari, S., Aris-
Brosou, S., Moon, T.W., 2011. The metabolic consequences of hepatic AMP-kinase 
phosphorylation in rainbow trout. PLoS One 6(5): 1-11. 
doi:10.1371/journal.pone.0020228 
Pollock, M.S., Fisher, S.E., Squires, A.J., Pollock, R.J., Chivers, D.P., Dube, M.G., 2008. 
Relative body size influences breeding propensity in fathead minnows: Implications 
for ecotoxicology testing procedure. Water Qual. Res. J. Canada 43: 257–264. 
Pandhare, J., Cooper, S.K., Donald, S.P., Phang, J.M., 2010. Regulation and Function of 
Proline Oxidase under Nutrient Stress. J Cell Biochem. 107: 759–768.  
Reece, Jane B, and Neil A. Campbell. Campbell Biology. Boston: Benjamin Cummings / 
Pearson, 2011. Print. 
148 
 
Renquist, B.J., Zhang, C., Williams, S.Y., Cone, R.D., 2013. Development of an assay for 
high-throughput energy expenditure monitoring in the zebrafish. Zebrafish 10: 343–
52. doi:10.1089/zeb.2012.0841 
Roa, J., Tena-Sempere, M., 2010. Energy balance and puberty onset: emerging role of 
central mTOR signaling. Trends Endocrinol. Metab. 21: 519–28. 
doi:10.1016/j.tem.2010.05.003 
Roberts, L., Bostrom, P., O’Sullivan, J.F., Schinzel, R.T., Lewis, G.D., Dejam, A., Lee, 
Y.K., Palma, M.J., Calhoun, S., Georgiadi, A., Chen, M.H., Ramachandran, V.S., 
Larson, M.G., Bouchard, C., Rankinen, T., Souza, A.L., Clish, C.B., Wang, T.J., 
Estall, J.L., Soukas, A.A., Cowan, C.A., Spiegelman, B.M., Gerszten, R.E. 2014. β -
Aminoisobutyric Acid Induces Browning of White Fat and Hepatic b -Oxidation and 
Is Inversely Correlated with Cardiometabolic Risk Factors. Cell Metabolism. 19: 96–
108. 
Rochfort, S., 2005. Metabolomics reviewed: A new “Omics” platform technology for 
systems biology and implications for natural products research. J. Nat. Prod. 68: 
1813–1820. 
Ruan, C.H., Dixon, R.A., Willerson, J.T., Ruan, K.H., 2010. Prostacyclin therapy for 
pulmonary arterial hypertension, Tex. Heart Inst. J. 37: 391–399. 
Ruzzante, D.E. and Doyle, R.W., 1991. Rapid behavioral changes in medaka (Oryzias 
latipes) caused by selection for compeptitive and non-competitive growth. Evolution. 
45(8): 1936-1946.  
Scheurer, M., Michel, A., Brauch, H.J., Ruck, W., Sacher, F., 2012. Occurrence and fate 
of the antidiabetic drug metformin and its metabolite guanylurea in the environment 
and during drinking water treatment. Water Res. 46: 4790–4802. 
doi:10.1016/j.watres.2012.06.019 
Schulz, H. Oxidation of fatty acids in eukaryotes. In: Biochemistry of Lipids, Lipoproteins 
and Membranes (5th Edition), pp. 131-154 (D.E. Vance and J. Vance (eds.), Elsevier, 
Amsterdam). 2008. Print. 
149 
 
Seifarth, C., Schehler, B., Schneider, H.J., 2013. Effectiveness of metformin on weight 
loss in non-diabetic individuals with obesity. Exp. Clin. Endocrinol. Diabetes 121: 
27–31. doi:10.1055/s-0032-1327734 
Shima, A., Shimada, A., 1994. The Japanese Medaka , Oryzias latipes , as a New Model 
Organism for Studying Environmental Germ-cell Mutagenesis. Env Health Prosp. 
33–35. 
Shu, Y., Sheardown, S. a S., Brown, C., Owen, R.P., Zhang, S., Castro, R. a, Ianculescu, 
A.G., Yue, L., Lo, J.C., Burchard, E.G., Brett, C.M., Giacomini, K.M., 2007. Effect 
of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. 
J. Clin. Invest. 117: 1422–31. doi:10.1172/JCI30558DS1 
Sorensen, P.W., Hara, T.J., Stacey, N.E., 1987. Extreme olfactory sensitivity of mature 
and gonadally-regressed goldfish to a potent steroidal pheromone, 17 α,20 β-
dihydroxy-4-pregnen-3-one. J. Comp. Physiol. A 160: 305–313. 
doi:10.1007/BF00613020 
Strom, S. Old pills finiding new medicine cabinets. The New York Times Technology 
News 18 May 2005. Print. 
Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, 
rosiglitazone, pioglitazone, D- chiro-inositol) for women with polycystic ovary 
syndrome, oligo amenorrhoea and subfertility. CochraneDatabase of Systematic 
Reviews 2012, Issue 5. Art. No.: CD003053. DOI: 
10.1002/14651858.CD003053.pub5.  
Tanwar S., Di Carro M., Ianni C., Magi E. (2014) Occurrence of PCPs in Natural Waters 
from Europe. In: Díaz‐Cruz M., Barceló D. (eds) Personal Care Products in the 
Aquatic Environment. The Handbook of Environmental Chemistry, vol 36. Springer, 
Cham. 
Ternes TA, Kreckel P, Mueller J. 1999. Behaviour and occurrence of estrogens in 
municipal sewage treatment plants— II. Aerobic batch experiments with activated 
sludge. Sci Total Environ 225:91–99. 
150 
 
Testa B, Jenner P. 1978. Novel drug metabolites produced by functionalization reactions: 
Chemistry and toxicology. Drug Metab Rev 7:325–369. 
Thomas D, Cherest H, Surdin-Kerjan Y (Mar 1991). "Identification of the structural gene 
for glucose-6-phosphate dehydrogenase in yeast. Inactivation leads to a nutritional 
requirement for organic sulfur". The EMBO Journal. 10 (3): 547–53. 
Toda, K., Kokushi, E., Uno, S., Shiiba, A., Hasunuma, H., Fushimi, Y., 
Wijayagunawardane, M.P.B., Zhang, C., Yamato, O., Taniguchi, M., Fink-
Gremmels, J., Takagi, M. 2017. Gas Chromatography-Mass Spectrometry for 
Metabolite Profiling of Japanese Black Cattle Naturally Contaminated with 
Zearalenone and Sterigmatocystin. Toxins. 9: 1-13. 
Tosca, L., Froment, P., Rame, C., McNeilly, J.R., McNeilly,  a S., Maillard, V., Dupont, 
J., 2011. Metformin decreases GnRH- and activin-induced gonadotropin secretion in 
rat pituitary cells: potential involvement of adenosine 5’ monophosphate-activated 
protein kinase (PRKA). Biol. Reprod. 84: 351–62. 
doi:10.1095/biolreprod.110.087023 
Trautwein, C., Berset, D., Wolschke, H., 2014. Occurrence of the antidiabetic drug 
Metformin and its ultimate transformation product Guanylurea in several 
compartments of the aquatic cycle. Environ. Int. 70, 203–212. 
doi:10.1016/j.envint.2014.05.008 
Tyagi, R., Rana, P., Gupta, M., Bhatnagar, D., Srivastava, S., Roy, R., Khushu, S., 2014. 
Chemico-Biological Interactions H NMR spectroscopic analysis detects metabolic 
disturbances in rat urine on acute exposure to heavy metal tungsten alloy based 
metals salt. Chemico Biol Int.  211: 20–28. doi:10.1016/j.cbi.2013.12.016 
Valeem, EE., 2012. Distribution of arachidic acid in different algal physical of Pakistan, 
Int. J. Physiol. Phycochem. 8: 73–78. 
Verlicchi, P., Aukidy, M. Al, Zambello, E., 2012. Science of the Total Environment 
Occurrence of pharmaceutical compounds in urban wastewater : Removal , mass load 
and environmental risk after a secondary treatment — A review. Sci. Total Environ. 
151 
 
429: 123–155. doi:10.1016/j.scitotenv.2012.04.028 
Viollet, B., Guigas, B., Garcia, N.S., Leclerc, J., Foretz, M., Andreelli, F., 2012. Cellular 
and molecular mechanisms of metformin : an overview. Clin Science. 270: 253–270. 
doi:10.1042/CS20110386 
Volz, D.C., Belanger, S., Embry, M., Padilla, S., Sanderson, H., Schirmer, K., Scholz, S., 
Villeneuve, D., 2011. Adverse outcome pathways during early fish development: a 
conceptual framework for identification of chemical screening and prioritization 
strategies. Toxicol. Sci. 123, 349–358. doi:10.1093/toxsci/kfr185 
USEPA. Treating contaminants of emerging concern: a literature review database. 
Washington DC: United States Environmental Protection Agency; 2012. 
Ussery, E.J., Bridges, K.N., Pandelides, Z., Kirkwood, A.E., Venables, B., Bonetta, D., 
Guchardi, J., Holdway, D., (In preparation). Uptake, depuration, and developmental 
effects of metformin on early life stages of Japanese medaka (Oryzias latipes). 
Anticipated submission: Aquatic Toxicology, June 2018.  
Ussery, E.J., Bridges, K.N., Pandelides, Z., Kirkwood, A.E., Venables, B., Bonetta, D., 
Guchardi, J., Holdway, D., (In preparation). Developmental effects of guanylurea, 
and guanylurea-metformin mixtures on early life stages of Japanese medaka (Oryzias 
latipes). Anticipated submission: Environmental Science and Technology, July 2018. 
Wakamatsu, Y., Inoue, C., Hayashi, H., Mishima, N., Sakaizumi, M., and Ozato, K., 2003 
Establishment of new medaka (Oryzias latipes) stocks carrying genotypic sex markers. 
Environ Sci.10(5): 291-302. 
WHO, 2015. http://www.whocc.no/atcddd/, last accessed October 2015 
Woo, S., Jeon, H.Y., Lee, T.K., Kim, S.R., Lee, S., Yum, S., 2011. Expression profiling of 
liver in Java medaka fish exposed to 17β-estradiol. Mol. Cell Toxicol. 7: 271-281. 
Xu, H., Fang, L., Hu, Z., Chen, Y., Chen, J., Li, F., Lu, J., Mu, J., Xie, P., 2012. Potential 
clinical utility of plasma amino acid profiling in the detection of major depressive 
disorder. Psychiatry Res. 200: 1054–1057. doi:10.1016/j.psychres.2012.05.027 
152 
 
Yui, K., Imataka, G., Kawasak, Y., Yamada, H., 2016. Increased ω -3 polyunsaturated 
fatty acid / arachidonic acid ratios and upregulation of signaling mediator in 
individuals with autism spectrum disorders. Life Sciences. 145: 205–212. 
doi:10.1016/j.lfs.2015.12.039 
Zagorska, A., 2010. New roles for the LKB1-NUAK pathway in controlling myosin phos- 
phatase complexes and cell adhesion. Sci. Signal. 3, ra25.  
Zhang, B. B., Zhou, G. & Li, C., 2009. AMPK: an emerging drug target for diabetes and 
the metabolic syndrome. Cell Metab. 9: 407–416. 
Zhang, L., Ge, L., Parimoo, S., Stenn, K., Prouty, S.M., C, S.B.T.R., 1999. Human 
stearoyl-CoA desaturase: alternative transcripts generated from a single gene by 















Appendix A: 7-day metformin toxicity testing 
Table A1: Percent hatch in Japanese medaka embryos exposed to various concentrations 
of metformin.  
Conc. (µg/L) % hatch after 7 days % hatch after 8 days % hatch after 9 days 
Control 17.5 50 95 
SC 5 70 97 
8 30 55 100 
40 45 45 92 
200 45 40 95 
1000 35 50 100 






Figure A1: Larval (7 dph) medaka from control treatment and from 5,000 µg · L-1 




Appendix B: Embryo-larval growth study 
Table B1: Percent hatchability in Japanese medaka embryos exposed to various 
concentrations of metformin.  
Metformin Concentrations 
(µg/L) % hatchability 












Figure B1: Mean length (mm) of 7 day old adult Japanese medaka (± SE) by treatment 
concentration (n = 80/treatment) An asterisk * denotes significantly different groups from 




Appendix C: Life-cycle reproductive results with error bars 
 
Figure C1: Cumulative reproductive output normalized to reproductive by treatment 
concentration (n = 14 control females; 3, 3.2 µg· L-1 metformin females; remainder of the 
treatments contained 9 reproductive females each). Cumulative egg data spans 10 
collection days. Data points represent the replicate means per treatment (± SE).  
 
